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ABSTRACT

ARTICLE HISTORY

Ebola virus (EBOV) is an extremely contagious pathogen and causes lethal hemorrhagic fever
disease in man and animals. The recently occurred Ebola virus disease (EVD) outbreaks in the
West African countries have categorized it as an international health concern. For the virus
maintenance and transmission, the non-human primates and reservoir hosts like fruit bats have
played a vital role. For curbing the disease timely, we need effective therapeutics/prophylactics,
however, in the absence of any approved vaccine, timely diagnosis and monitoring of EBOV
remains of utmost importance. The technologically advanced vaccines like a viral-vectored
vaccine, DNA vaccine and virus-like particles are underway for testing against EBOV. In the
absence of any effective control measure, the adaptation of high standards of biosecurity
measures, strict sanitary and hygienic practices, strengthening of surveillance and monitoring
systems, imposing appropriate quarantine checks and vigilance on trade, transport, and
movement of visitors from EVD endemic countries remains the answer of choice for tackling
the EBOV spread. Herein, we converse with the current scenario of EBOV giving due emphasis
on animal and veterinary perspectives along with advances in diagnosis and control strategies
to be adopted, lessons learned from the recent outbreaks and the global preparedness plans.
To retrieve the evolutionary information, we have analyzed a total of 56 genome sequences of
various EBOV species submitted between 1976 and 2016 in public databases.
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1. Introduction
The entry of Ebola virus disease (EVD) was ﬁrst marked in
the year 1976 (Vogel & Viale 2014) and since then it is a
highly contagious virus infection leading to the death of
large numbers of humans (Muyembe-Tamfum et al.
2012; Bausch & Schwarz 2014; Bellizzi 2014; Dhama, Malik,
et al. 2015). The disease is zoonotic, and evidence suggests the involvement of fruit bats as the main reservoir
(Towner et al. 2007; Towner et al. 2008; Spengler et al.
2016; Hassanin et al. 2016; Judson et al. 2016). Although it
affects both human and non-human primates, the major
outbreaks have been reported in humans, mostly in
Western Africa (Weingart et al. 2013; Feldmann & Feldmann 2014; Shrivastava et al. 2015a, 2015b). The Ebola
virus (EBOV) has been listed as Category A agent warranting biosafety containment level 4 (BSL4) for the handling
of suspected samples. The disease symptoms start with
fever, pain in stomach with vomiting and diarrhea,

CONTACT Kuldeep Dhama

kdhama@rediffmail.com; Yashpal Singh Malik

KEYWORDS

Ebola virus; Ebola
hemorrhagic fever; public
health; transmission; carriers;
epidemiology; diagnosis;
vaccines; treatment; control;
preparedness

bleeding, intravascular coagulation, multisystem organ
failure, and hypovolemic shock and in terminal cases, the
patient succumbs to death (Mendoza et al. 2015). The
virus spreads from diseased to normal persons through
direct contact and infected materials. This virus tends to
persist in body leading to further complications such as
loss of vision (Shantha et al. 2017), hearing (Hebert et al.
2017), etc. along with transmission through semen from
male to female (Hartmann et al. 2017) and to fetus at the
time of pregnancy (Friedrich 2016; Wiwanitkit 2016).
A major outbreak of EBOV, which occurred in 2014
in Western African countries, transpired to several
other countries in a short span of time, culminating it
as an alarming situation world over. The spread of
EBOV was so rapid that family members and the community around infected people suffered sternly (Kuhn
et al. 2010; Weingart et al. 2013; Gatherer 2014). Of
note, affected young children showed comparatively
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shorter incubation period and rapid course of disease
with high mortality (Team 2015). Owing to global trade
and tourism, there is every possible opportunity that
EBOV can spread to other continents where it may
lead to massive outbreaks. The epidemics which
occurred over the past few years should serve as an
eye-opener to the world so that everyone is well prepared for the next pandemic if any occurs. In this direction, it is important that the nature of the agent, its
evolution pattern, and pathway of spread must be
understood at a subtle level. To deal with such a highly
spreading disease we must be equipped with rapid
state-of-art diagnostics which are useful at the bedside
of the patient, ultimately beneﬁting in opting appropriate control and treatment measures. Likewise, there is
an urgent need to have effective and adequate vaccines to provide protection to the population at high
risk. Therapeutic strategies must be evaluated for their
high potential.
Currently, there are ﬁve distinct EOBV species which
have been described, and four of them (Zaire ebolavirus, Sudanebolavirus, Ta€ı Forest ebolavirus, and Bundibugyo ebolavirus) cause disease in humans, whereas the
Reston ebolavirus is known to cause disease in nonhuman primates solely. We here converse comprehensively over the developments ensued in understanding
the etiopathology of EVD, ecology, prevention and
control strategies along with various therapeutic
alternatives.

2. The virus and its genome
EBOV belongs to the order Mononegavirale (singlestranded, non-segmented, negative-sense RNA virus)
of the family Filoviridae, genus Ebolavirus. Other members of the family include Marburgvirus and Cuevavirus,
of which Marburgvirus has also been implicated in
causing hemorrhagic diseases similar to EBOV, and
both of these are ﬁlamentous shape viruses. The genus
Marburgvirus consists of a species Marburg marburgvirus with two viruses viz., Marburg virus (MARV) and
Ravn virus (RAVV). The genus Cuevavirus consists of a
single species – Lloviu cuevavirus with Lloviu virus
(LLOV). The EBOV was ﬁrst isolated in 1976 near Zaire
valley in the Democratic Republic of Congo (Zaire)
rooting its name from the place of isolation (Kuhn et al.
2010), initially named as an Ebola-like virus which was
later changed into EBOV in the year 2002. The genus
Ebolavirus consists of ﬁve species viz., (1) Zaire ebolavirus (Zaire virus – ZEBOV), (2) Sudan ebolavirus (Sudan
virus – SUDV), (3) Reston ebolavirus (Reston virus –
RESTV), (4) Ta€ı Forest ebolavirus (Ta€ı Forest virus –
TAFV), and (5) Bundibugyo ebolavirus (Bundibugyo
^te d'Ivoire ebolavirus (CIEBOV)
virus – BDBV) and Co
(Kuhn et al. 2013; Bausch & Schwarz 2014; Bukreyev
et al. 2014; Kuhn, Andersen, et al. 2014; Kuhn, Bao,
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et al. 2014; http://www.ictvonline.org/virusTaxonomy.
asp). The genetic diversity among species in the genus
Ebolavirus ranges between 25% and 35% (Grard et al.
2011). Among the ﬁve species, ZEBOV and SUDV are
extremely deadly, of which the former is most dangerous with more than 90% lethality (Bellizzi 2014; Toit
2014; Safari et al. 2015). ZEBOV was frequently documented in Central Africa and has caused the major outbreaks recently in Western African countries like
Nigeria, Liberia, Guinea, Senegal, and Sierra Leone
(Baize et al. 2014).
As shown in Figure 1, structurally the virions of ﬁlovirus show pleomorphism which includes long ﬁlaments
(Latin-ﬁlum means thread), shaped like a ‘6’, a ‘U’, or a
circle. Viral ﬁlaments are 80 nm in diameter with up to
14,000 nm in length and are enveloped in a lipid membrane (http://www.cdc.gov/vhf/virus-families/ﬁloviridae.
html). The genome of EBOV is 19 kb in length, consists
of seven genes which are arranged as – 3" (leader)- NPVP35-VP40-GP-VP30-VP24-L-(trailer) 5" (Volchkov et al.
1999). These seven open reading frames encode structural nucleoprotein (NP), envelope glycoprotein (GP),
and matrix proteins like viral proteins (VP24) (membrane-associated protein) and VP40. Except for GP, each
of these genes encodes a single protein product. Apart
from structural proteins, L (RNA polymerase), VP30 and
VP35 (both polymerase matrix proteins) correspond to
the major non-structural protein. These proteins exhibit
different roles in virus pathogenesis like VP24 inhibits
interferon signaling, VP35 is an antagonist of interferon,
whereas VP40 has a role in budding and release of the
virus (Feldmann & Geisbert 2011). VP40 has been
recently found in the extracellular region like exosome
that can affect the immune system of the host (Pleet
et al. 2017). The GP gene codes for three different versions of GP, namely GP (contains GP1 attachment protein and the GP2 fusion/entry protein), soluble form
(sGP – is produced from the unedited RNA transcript)
and small soluble form (ssGP – is a truncated version of
sGP). Most of these proteins have multiple functions. NP
facilitates the genomic RNA encapsidation to form RNP
complex (RNA + NP + + L), which plays an essential role
in virus replication. The GP and VP40 are essential components of the viral envelope. GP has a role in virus
attachment, entry, causing cell rounding, down-regulating host surface proteins, causes inﬂammation, cell
damage, and cytotoxicity (Casillas et al. 2003; Geisbert
et al. 2009; Olival et al. 2013). The nucleocapsid consists
of the viral RNA complexed with ﬁve proteins, namely
NP, VP24, VP30 and VP35, and L (Sanchez et al. 1993;
Lee & Saphire 2009; Bharat et al. 2012; Basler 2014;
Brauburger et al. 2014; Gallaher & Garry 2015; Dong
et al. 2015; Jun et al. 2015). Unlike inﬂuenza A virus, the
rate of genetic change is very slow in EBOV, but this
virus diverged several thousand years ago (Suzuki &
Gojobori 1997; Taylor et al. 2011).
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Figure 1. Structure of Ebola virus and its genome. Ebola virus possesses negative-sense RNA genome with exceptionally 14000 nm
length with 3' nucleoprotein and 5' RNA polymerase end.

2.1. Evolutionary picture of Ebolaviruses
To retrieve the evolutionary information, we have analyzed a total of 56 genome sequences of various EBOV
species submitted between 1976 and 2016 in public
database, wherein the Zaire, Sudan, Reston, Ta€ı, and
Bundi EBOVs formed distinct clades (Figure 2). The
ZEBOV strains organized into two distinct sub-clades,
sub-clade 1 comprising of the isolates from Gabon and
the Democratic Republic of Congo and sub-clade 2
clubed Sierra Leone and Liberia isolates (Figure 2). The
evolutionary divergence between the species was estimated using the Maximum Composite Likelihood
model (Tamura et al. 2004). The number of transversional substitutions per site from the average of overall
sequence pairs between groups was obtained. The
rate variation among sites was modeled with a gamma
distribution (shape parameter = 1). Codon positions
included were 1st + 2nd + 3rd + Noncoding. There was
a total of 17,999 positions in the ﬁnal data-set. Evolutionary analyses were conducted in MEGA6 (Tamura
et al. 2013). Further, the analysis revealed that the Ta€ı
and Bundi EBOVs remain closely related to 17.8%
mean group diversity; the ZEBOV had the mean group
diversity of 26.1% and 26.8%, respectively with Ta€ı and

Bundi EBOV. The SUDV outgroup from ZEBOV, Ta€ı, and
Bundi EBOVs revealed mean group diversity of 36.3%,
37.4%, and 37.6%, respectively. Similarly, RESTV outgroup from Zaire, Ta€ı, and Bundi EBOVs came up with
mean group diversity of 34.1%, 35.1%, and 34.8%,
respectively. Likewise, the mean group diversity
between Sudan and Reston EBOVs was found to be
36.6%.

2.2. Epidemiology, transmission, and spread
It is evident that since the ﬁrst report of EVD, the number of ratiﬁed cases has increased several folds. The
causality cases of EVD almost doubled in Africa in comparison to the earlier reported cases of the last four
decades (6458 deaths out of 12,299 cases; MuyembeTamfum et al. 2012; Tambo et al. 2014; Bellizzi 2014)
and the cases reported between 2014 and 2016
(12,922 deaths out of 31,079 cases) (CDC 2015)
(Table 1). The 2014–2015 outbreak was assumed to be
the biggest epidemic in the history of this disease
(Gatherer 2014; Zhang & Wang 2014; Elstona et al.
2017). Though several strains of EBOV have been identiﬁed in the past, the 2014–2015 outbreak affecting
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Figure 2. Evolutionary relationships of Ebola virus complete genomes. The evolutionary history was inferred using the NeighborJoining method (Saitou & Nei 1987). The optimal tree with the sum of branch length = 1.06917633 is shown. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) is shown next to the branches
(Felsenstein 1985). The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to
infer the phylogenetic tree. The evolutionary distances were computed using the p-distance method (Nei & Kumar 2000) and are in
the units of the number of base differences per site. The analysis involved 56 nucleotide sequences. Codon positions included were
1st + 2nd + 3rd + Noncoding. All positions containing gaps and missing data were eliminated. There was a total of 17,999 positions
in the ﬁnal data-set. Evolutionary analyses were conducted in MEGA6 (Tamura et al. 2013).
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Table 1. Outbreaks of Ebolavirus genus between 1976 and March 2016.
Ebola subtype
Recent outbreaks
(since 2014)
Ebolavirus

Number of
transmission
events

–

Country

Ebolavirus

1

Multiple countries
mainly three West
African countries,
namely
Guinea, Liberia, Sierra
Leone
DRC

Outbreaks
between 1976
and 2013
Bundibugyo virus
Reston virus

2
7

Sudan virus

8

Ta€ı Forest virus

1

Zaire virus
Total

15

Reported
number of
human cases

Reported number
(%) of deaths
among cases

28,652

11,325 (40)

66

49 (74)

DRC, Uganda
Philippines, USA, Italy

185
13

50 (27)
0 (0)

South Sudan, Uganda,
England
C^ote d'Ivoire (Ivory
Coast)
Republic of Congo, DRC,
Russia, Gabon,
South Africa

779

412 (53)

1

Remarks

Data between March 2014 and 27 March 2016.
Seven countries (Italy, Mali, Nigeria, Senegal,
Spain, the United Kingdom, and the United
States of America) have previously reported a
case or cases imported from a country with
widespread and intense transmission.
August–November 2014; the outbreak was
unrelated to the outbreak of Ebola in West
Africa.

Four outbreaks in monkeys only; one outbreak
in pigs with antibody detection in six workers;
two out breaks in moneys with seven people
developed antibodies.

0 (0)

1383

1086 (79)

31079

12922

Source: http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html; http://apps.who.int/ebola/current-situation/ebola-situation-report-30-march2016

mainly Western African countries (Guinea, Sierra Leone,
Liberia, Senegal, and Nigeria) was conﬁrmed due to
ZEBOV (Bellizzi 2014). This strain was the ﬁrst EBOV
which caused the historic 1976 Ebola case affecting a
middle age school teacher in the Democratic Republic
of the Congo (Johnson 1978). Identifying the severity
and out-of-control situation about EVD, the World
Health Organization declared it as a ‘Public Health
Emergency of International Concern’ (PHEIC). Owing to
its high virulence and fast transmission capability, it is
categorized under ‘class A’ bio-weapon organism (Balmith et al. 2016) and thus making it essential to have
real-time monitoring of EVD cases and to look into any
connectivity among the cases. For this, use of smart
mobile phones reporting of EVD cases in West Africa
was encouraged by epidemiologists as an effective
technique. Use of social network analysis in this way
will certainly help in understanding disease spread in a
better way (Kangbai 2016). The case fatality rate
observed in Ebola-affected cases in different countries
varied between 25% and 100%.
The countries affected during 1976–2016 are
depicted in Figure 3 and a historical timeline of EBOV
is presented in Figure 4. The disease outbreaks caused
by different EBOV species are given in Table 1 and
chronological data of EBOV cases and fatality since its
ﬁrst incidence is summarized in Table 2.

2.2.1. Zaire ebolavirus (ZEBOV)
The ﬁrst known Ebola outbreak occurred in 1976 in
Sudan (later the causative agent was classiﬁed under
Sudan virus – SUDV) and the Democratic Republic of

the Congo (DRC; previously known as Zaire) (Report of
an International Commission 1978; Report of a WHO/
International Study Team 1978) (Figures 3 and 4). In
the DRC outbreak (between September and October
1976), 318 cases of acute viral hemorrhagic fever (VHF)
with 280 deaths (case fatality rate – CFR 88%) occurred
in and around the Yambuku region. The duration of
the clinical disease was about one week with non-speciﬁc symptoms for the initial four days followed by a
severe sore throat, maculopapular rash, abdominal
pain, and bleeding from multiple sites – mainly from
the gastrointestinal tract. The causative agent could be
isolated from eight cases using Vero cell cultures and
was named as Ebola virus (Report of an International
Commission 1978). The index case (the ﬁrst identiﬁed
case) was a 44-year-old male instructor who has been
treated for presumptive malaria at the Yambuku
hospital, and from there the subsequent outbreaks
emerged.
The ﬁrst EBOV was isolated in 1976 (isolate E718)
from the blood sample of a 42-year-old Belgian nursing
sister (patient No. 718) who was working at Mission
Hospital, Yambuku, DRC. The sister (Myriam Louise
Ecran) was one of the ﬁrst victims of Ebola hemorrhagic fever (EHF) and died on 30 September 1976
(CDC 2015; www.bbc.com/news/magazine-28262541).
Researchers decided to name the virus to the nearby
river – the Ebola, rather than the village name to avoid
stigma to that village. In Belgian, the river named as
l'Ebola (the indigenous Ngbandi name is Legbala)
means ‘white water’ or ‘pure water’ (Report of an International Commission 1978; Report of a WHO/
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Figure 3. Ebola-affected countries on the world map. The coloured area depicts Ebola presence from 1976 to 2016.

International Study Team 1978). Since that time, the
name Ebola has been used (http://www.nature.com/
scitable/blog/viruses101/the_scientist_who_discovere
d_ebola). The EBOV was initially categorized as ‘Marburg-like’ due to the morphological resemblance
(Johnson et al. 1977). Initially, it was presumed that the
DRC and Sudan outbreaks were caused by the same

strain of the virus (the distance between Yambuku and
Nzara is about 800 km) but, later it was realized that
there is involvement of two distinct species, namely
Zaire Ebola virus (Ebola virus – ZEBOV) and Sudan ebolavirus (Sudan virus – SUDV), respectively (McCormick
et al. 1983; Pourrut et al. 2005; Muyembe-Tamfum et al.
2012).

Figure 4. Historical timeline of Ebola virus. The number of outbreaks in Sudan, the Democratic Republic of Congo, Uganda, and Tai
Forest are dipcted.
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Table 2. Chronological data of Ebola virus cases and fatality since its ﬁrst incidence.
Years
1976
1977
1979
1989–1990
1990
1994
1995
1996
1996–1997
1996
2000–2001
2001–2002
2002–2003
2003
2004
2007
2007–2008
2008
2008–2009
2011
2012
2012–2013
2014–2016

Country
Zaire
Sudan
England
Zaire
Sudan
Philippines
USA
Gabon
C^ote d'Ivoire Ivory Coast
Democratic Republic of Congo
Gabon
Gabon
South Africa
Uganda
Gabon
Republic of Congo
Republic of Congo
Republic of Congo
South Sudan
Russia
Democratic Republic of Congo
Uganda
Philippines
Democratic Republic of Congo
Uganda
Uganda
Democratic Republic of Congo
Uganda
United States of America
Spain
United Kingdom
Italy
Guinea
Sierra Leone
Senegal
Mali
Liberia
Nigeria

Total

Cases reported
318
284
1
1
34
3
4
52
1
315
37
60
2
425
65
57
143
35
17
1
264
149
6
32
1
11
36
6
4
1
1
1
3814
14124
1
9
10678
20
31013

Deaths
280
151
0
1
22
0
0
31
0
250
21
45
1
224
53
43
128
29
7
1
187
37
0
15
1
4
13
3
1
0
0
0
2544
3956
0
6
4810
8
12872

Case fatality rate
88%
53.1%
0%
100%
64.7%
0%
0%
59.6%
0%
71.4%
56.7%
75%
50%
52.7%
81.5%
75.4%
89.5%
82.8%
41.1%
100%
70.8%
24.8%
0%
46.8%
100%
36.3%
36.1%
50%
25%
0%
0%
0%
66.7%
28%
0%
66.6%
45%
40%
41.5%

Note: Data compiled from WHO situation reports apps.who.int/ebola/ebola-situation-reports?m = 20141121 and CDC updates on Ebola virus https://
www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/previous-updates.html

The subsequent outbreak of EBOV occurred in June
1977 in Tanda (325 km from Yambuku), DRC and a
nine-year-old girl died with typical clinical signs of EHF.
No secondary cases were identiﬁed (Heymann et al.
1980). Later, a less extensive form of EBOV occurred,
between July and October 1979, in Nzara and Yambio
(25 km away from Nzara), wherein 22 deaths occurred
out of 34 cases with CFR of 65% (Baron et al. 1983).
After 15 years of pause, three EBOV outbreaks
occurred in northeastern Gabon between 1994 and
1997. The ﬁrst epidemic (fall 1994) occurred in
Mekouka along with co-infection of yellow fever virus.
In this epidemic, 49 cases of EVD, with 29 deaths (CFR
59%) occurred. A second epidemic (spring 1996) in
Mayibout caused 31 cases with 21 deaths (CFR 68%)
and of note a chimpanzee was suspected as the index
case. The third epidemic (fall 1996) occurred in Booue
and caused 60 cases with 45 deaths (CFR 75%). Several
chimpanzees died in this area, and EBOV-antigen could
be detected from one of the skin samples by immunostaining (Georges et al. 1999). Partial GP gene
sequence analysis revealed that the causative agent
behind all these three outbreaks was EBOV (Georges-

Courbot et al. 1997). Additionally, this outbreak also
led to the death of a nurse in South Africa which was
transmitted from an EBOV-infected Gabonese physician working in Libreville and traveled to Johannesburg for treatment (WHO 1996; Pourrut et al. 2005).
Afterwards, one of the largest EBOV outbreaks
occurred in the city of Kikwit, DRC (»500 km southeast
of Kinshasa), between January and July 1995 with 255
deaths out of 315 cases (CFR 81%). Of note, a 42-yearold male charcoal worker was identiﬁed as index case
who had acquired infection from some natural reservoir such as bats, as no great apes were found in that
region (Guimard et al. 1999; Khan et al. 1999).
^te d'Ivoire, between 1996 and 1997,
In Ta€ı Forest, Co
autopsy samples from several species of vertebrates
including bats, rodents, insectivores, monkeys, and
birds were screened, and anti-EBOV IgG could be
detected only from a Colobe bai monkey (red colobus,
Colobus badius) (Pourrut et al. 2005). During ecological
studies in the Central African Republic (CAR) in 1998,
242 vertebrates include bats, rodents and insectivores
were captured and organs tested for the presence of
EBOV nucleic acid by GP and L genes-based reverse
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transcription-polymerase chain reaction (RT-PCR).
Seven animals including six mice (Mus setulosus and
Praomys spp.) and a shrew (Sylvisorex ollula) were
found harboring EBOV (Morvan et al. 1999).
Between October 2001 and December 2003, at least
ﬁve EBOV outbreaks occurred in the border areas of
northeast Gabon and northwest Republic of Congo
(RC) with 313 cases and 265 deaths (CFR 85%). The ﬁrst
outbreak (October 2001–May 2002) occurred in both
Gabon and RC; the outbreak occurred as multiple independent epidemic chains with 92 cases and 70 deaths
(CFR 77%). Epidemiologic investigations suggest the
possible involvement of carcasses of wild animals
(bushmeat) including duikers, chimpanzees, and
gorillas in the index patients. In January 2002, in
Franceville, a single case was reported in the south of
Gabon (Nkoghe, Nnegue, et al. 2005) and the remaining four outbreaks occurred only in RC.
In a later outbreak (Entsiami – January 2002 to June
2002), a total of 30 cases with 25 deaths (CFR 83%)
occurred; a gorilla and a duiker were suspected to be
the source for the index cases. In the following outbreak (Oloba – May to June 2002), 13 cases with 12
deaths (CFR 92%) occurred, and a chimpanzee was
identiﬁed as the source for index case. In another outbreak (Mbomo and K
ell
e – December 2002 to April
2003) 143 cases with 129 deaths (CFR 90%) occurred;
gorillas and duikers were suspected to be the source of
infection for the index cases. The last outbreak
(Mbanza and Mbomo – November 2003 and December
2003) caused 35 cases with 29 deaths (CFR 83%).
However, the source of infection could not be
traced (http://www.who.int/wer/2003/en/wer7826.pdf;
Formenty et al. 2003; Leroy et al. 2004; Pourrut et al.
2005; Rouquet et al. 2005; Nkoghe, Formenty, et al.
2005). Sequencing analysis of GP gene of EBOV
revealed that the above ﬁve human outbreaks originated from distinct animal sources and viral strains
(Leroy et al. 2004). These Gabon-RC cross-border outbreaks were marked by large wildlife epizootics associated with over 80% mortality especially in great apes
(Leroy et al. 2004; Rouquet et al. 2005; Bermejo et al.
2006; Lahm et al. 2007; Grard et al. 2011).
After the ﬁrst outbreak in the forest zone of GabonRC, an Animal Mortality Monitoring Network was created. The analysis of the samples recovered between
August 2001 and June 2003 revealed that 10 gorillas, 3
chimpanzees, and 1 duiker were positive for EBOV
infection (Rouquet et al. 2005). Another group of
researchers from Centre International de Recherches
M
edicales de Franceville, Gabon analyzed a total of 34
carcasses in the same period, and 14 (10 gorillas, 3
chimpanzees, and 1 duiker) were found positive for
EBOV infection (Pourrut et al. 2005).
In the seroprevalence study of EBOV in 20 species of
non-human primates between 1985 and 2000 in
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Cameroon, Gabon, and the RC, the wild chimpanzees
showed 12.9% positivity. Also, few other monkey species (ﬁve drills, one baboon, one mandrill, and one Cercopithecus sp.) were also positive indicating the
complexity of the EBOV circulation and the possibility
of involvement of more reservoir species (Leroy et al.
2004; Pourrut et al. 2005).
To identify the viral reservoir in the multiple outbreaks of Ebola in Gabon and RC between 2001 and
2005, the investigation was carried out from samples
of over 1000 small vertebrates. Anti-EBOV IgG, as well
as EBOV-speciﬁc RNA sequences, were detected from
three different bat species (Hypsignathus monstrosus,
Epomops franqueti, and Myonycteris torquata). The
sequence conﬁrmation of EBOV indicates that bats
might serve as a natural reservoir of EBOV (Leroy et al.
2005; Pourrut et al. 2009). In a large-scale serological
survey from these three bat species which were captured between 2003 and 2006 in Gabon and RC 5%
EBOV infection positivity was shown, supporting their
potential reservoir status (Pourrut et al. 2007; Pourrut
et al. 2009). In a further extension of this study, samples
were analyzed for EBOV from nine species of bats
which were sampled between 2003 and 2008 and
among these, 4% of the total population sampled
belonged to six species (Epomops franqueti, Hypsignathus monstrosus, Myonycteris torquata, Micropteropus
pusillus, Mops condylurus, and Rousettus aegyptiacus)
which revealed anti-EBOV antibodies (Pourrut et al.
2009).
The EBOV reemerged in the Luebo region of DRC in
2007 and 2008, causing two successive outbreaks. The
2007 outbreak caused 264 cases with 187 deaths (CFR
71%) and re-occurred one year later with 32 cases with
15 deaths (CFR 47%). The suspected source of the
Luebo 2007 outbreak was fruit bats (Hypsignatus monstrosus and Epomops franqueti). The index source of
the 2008 outbreak could not be traced out. The analysis of whole-genome sequence results of viruses from
these two outbreaks conﬁrms them almost identical
(Grard et al. 2011).
Following this, the EBOV outbreak occurred in multiple villages in the DRC between July and November
2014 in Equateur province with a total of 69 cases with
49 deaths (CFR 71%). A pregnant woman was the index
case, and monkey meat was the suspected source of
the infection. A complete genome sequence from this
outbreak shared 99.2% and 96.8% identities with
EBOVs of 1995 outbreak in the DRC and current outbreak in West Africa, respectively (Maganga et al.
2014).
The recent EBOV-epidemic burst in West Africa
started in Guinea in late 2013 and spread to several
countries within a few months period (Cenciarelli et al.
2015). As of 13 April 2016, a total of 31,013 cases with
12,872 deaths (CFR 41.5%) have been reported. The
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widespread transmission occurred in three countries,
namely Liberia, Sierra Leone and Guinea (28,616 cases
with 11,310 deaths – CFR 40%). Very few travel-related
cases (36 cases and 15 deaths) have been reported in
seven countries, namely Italy, Mali, Nigeria, Senegal,
Spain, the United Kingdom, and the United States of
America)
(http://www.cdc.gov/vhf/ebola/outbreaks/
2014-west-africa/case-counts.html). The suspected index
case for these outbreaks was a two-year-old child
(http://www.who.int/csr/disease/ebola/ebola-6-months/
guinea/en/). The whole-genome sequencing of 99 samples from 78 affected individuals in Sierra Leone suggested the involvement of the West African variant of
EBOV in the current epidemic. The suspected source of
the outbreak was from an unknown animal reservoir.
The Sierra Leone outbreak originated from the introduction of two EBOV variants lineages (Gire et al. 2014).
Considering the highest risk to the national security
and public health concern, the US-NIAID, classiﬁed the
EBOV under Category A Priority Pathogens (https://
www.niaid.nih.gov/topics/biodefenserelated/biode
fense/pages/cata.aspx). Laboratory-acquired EBOV
infection also had been reported from Russia on two
occasions. It had emerged that in 1996, a female lab
technician carrying out the high-risk work, cut herself
when she drew blood from a horse that had been
infected with EVD and died quickly. In the second incident, a Russian lab worker died in 2004 while working
with EBOV-infected guinea pigs (https://www.washing
tonpost.com/national/health-science/2014/10/23/
ce409716-5945-11e4-b812-38518ae74c67_story.html;
http://www.theaustralian.com.au/news/world/thetimes/russians-died-in-ebola-weapons-lab/news-tory/
e426b0bd0064da5fe8c78e4d485c162c).

2.2.2. Sudan ebolavirus (Sudan virus – SUDV)
Sudan virus – SUDV (Sudan ebolavirus) and Ebola virus
– EBOV (Zaire ebolavirus) are related regarding clinical
disease but vary in serology, pathogenic potential, and
virological properties (Richman et al. 1983). In Sudan,
between June and November 1976, a large outbreak of
EHF occurred in Nzara, Maridi, and the surrounding
area and caused 284 cases with 151 deaths (CFR 53%).
The clinical disease observed in this outbreak was associated with high mortality (CFR 53%) and a prolonged
recovery period in survivors. A cotton factory worker in
Nzara was identiﬁed as the index case (Report of a
WHO/International Study Team 1978). The specimens
collected during the Sudan and DRC outbreaks were
sent to high-security laboratories in England (Microbiological Research Establishment, Porton Down), Belgium
(Institute of Tropical Medicine, Antwerp), and the
United States of America (CDC, Atlanta) for isolation
and identiﬁcation of the agent. All three laboratories
isolated a virus that morphologically resembled Marburg virus but was serologically distinct (Bowen et al.

1977; Emond et al. 1977; Johnson et al. 1977). In the
UK, one of the investigators accidentally pricked his
thumb while handling the samples and developed an
illness (Emond et al. 1977).
Between July and October 1979, SUVD outbreak
occurred in Nzara and Yambio of southern Sudan and
caused 34 cases with 22 deaths (CFR 65%). A 45-yearold man who had been employed in the Nzara textile
factory was the index case (Baron et al. 1983), and the
possible source of infection was bats (Pourrut et al.
2005).
An outbreak of VHF occurred between October
2000 and January 2012 from Gulu district (borders
Sudan), Uganda, and 425 infected cases were reported
with 224 deaths (CFR 53%). A concurrent outbreak of
SUDV and measles occurred in Yambio County of
southern Sudan between April and June 2004. A total
of 17 VHF cases and 7 deaths (CFR 41%) were reported
in Yambio payam. The CDC conﬁrmed the presence of
SUDV in this outbreak (WHO 2005). The index case
was a radio technician, and the source of the
outbreak was a baboon (Papio anubis) (WHO 2005).
During 2008, SUDV outbreak recurred in Kaluamba
with 37 cases and 16 deaths (CFR 44%). An 18-year-old
girl appeared to be an index case, but the source was
not known (Muyembe-Tamfum et al. 2012; Rewar &
Mirdha 2014).
In May 2011, a 12-year-old girl from Luwero,
Uganda, was admitted to the Hospital with symptoms
of VHF and died within three hours of admission. Evidence of infection with SUDV was conﬁrmed by RTPCR, antigen-detection ELISA, and virus isolation. Analysis of complete genome sequencing of the above
virus had 99.3% identity to the Gulu SUDV – 2000 virus.
The circumstantial evidence suggests that a bat was
the source of infection (Shoemaker et al. 2012).
In order to detect VHFs in Uganda, a surveillance
program was initiated in 2010 by the CDC, Atlanta,
USA, in collaboration with the Uganda Virus Research
Institute and the Uganda Ministry of Health (MacNeil
et al. 2011). Samples collected from the outbreak of
Kibaale, Uganda between July and August 2012,
yielded 11 laboratory conﬁrmed cases (SUDV infection)
with 4 deaths (CFR 36%). Complete genome analysis of
the above four clinical samples showed »99.9%
sequence identity with each other and »99.2% identity
with the SUDV Nakisimata (Uganda – 2011), and SUDV
Gulu (Uganda – 2000) isolates (Albarino et al. 2013). In
the same surveillance, the samples collected from an
outbreak in the relatively close districts of Luwero,
Jinja, and Nakasongola, Uganda in November 2012
yielded six laboratory conﬁrmed cases with three
deaths (CFR 50%). Sequence analysis of NP gene from
three serum samples revealed that they are nearly
»100% identical. Involvement of bats was suspected
~o et al. 2013).
for its transmission (Albarin
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2.2.3. Reston ebolavirus (Reston virus – RESTV)
In October 1989, 100 cynomolgus monkeys (Macaca
fascicularis) were transported from Manila, the Philippines to Reston, Virginia and placed in a quarantine
facility. During the quarantine, numerous macaques
died, due to concomitant infection of Ebola-related
ﬁlovirus (as per the recent classiﬁcation – Reston virus
or RESTV) and by simian hemorrhagic fever virus (SHFV
– an arterivirus) (CDC 1989). RESTV could be isolated at
least from ﬁve monkeys (Jahrling et al. 1990). This was
considered as the ﬁrst known EBOV outbreak that
occurred outside of Africa as well as in non-human primates (Miranda & Miranda 2011).
Between November 1989 and March 1990, active
infection of RESTV occurred in seven shipments of cynomolgus monkeys and further transmission to monkeys in quarantine facilities and many of them died.
Four animal handlers at a quarantine facility had antiRESTV antibodies (CDC 1989; Jahrling et al. 1990; CDC
1990a). Among these four cases, viremia developed in
one person on days 9, 10, and 11 post-inoculation
(WHO 2009). CDC has screened »2200 serum samples
from different monkey species from a variety of settings, and »10% had antibodies against at least one of
four ﬁlovirus test antigens (EBOV, SUDV, RESTV, and
Marburg virus) (CDC 1990b).
Studies were initiated to document transmission at
export facilities located in the Philippines. At one
export facility, within three months period (between
March and May 1990), out of 403 monkeys, 161 (40%)
died from RESTV as conﬁrmed in these animals. The
clinical manifestations observed in the outbreak
included diarrhea (50%), respiratory illness (34%), and
hemorrhage (1%) (Hayes et al. 1992). However, three
workers in the animal facility developed antibodies
against RESTV without any clinical signs (Miranda et al.
1991). The source of RESTV was not known (Rollin et al.
1999).
The next outbreak occurred in 1992. A batch of 55
cynomolgus monkeys was imported from a monkeybreeding company in the Philippines into Italy in
March 1992. Four monkeys died within a month, and
viruses isolated from three monkeys were conﬁrmed
as ﬁloviruses by electron microscopy. They were shown
to be antigenically related to EBOV by indirect immunoﬂuorescence assay (WHO 1992). Although two people developed virus-speciﬁc IgG antibodies, clinical
infections not observed (Miranda & Miranda 2011).
In March 1996, an imported cynomolgus monkey
that was held in a quarantine facility in Texas developed non-speciﬁc signs such as anorexia and lethargy
and died after three days. A second monkey also
showed similar kind of symptoms, and it was euthanized. RESTV was isolated from both the animals. No
viral antigen or RESTV-speciﬁc antibodies could be
detected from animal handlers. Also, during the laboratory investigation, as in 1989 and 1990, SHFV could
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have infected some of the animals (Rollin et al. 1999).
GP gene of RESTV isolated from the ﬁrst animal had
98.9% nucleotide identity with the 1989 RESTV (Sanchez et al. 1999). In a USA–Philippine Joint Investigation at the monkey export facility in the Philippines it
revealed that 14 out of 21 animal houses had infected
monkeys. Anti-RESTV antibodies and virus nucleic acid
could be detected from 3 out of 1732, and 132 of 1011
monkeys, respectively. Seroprevalence on animal handlers from monkey facilities and people with occupational exposure to pigs in USA, Italy, and the
Philippines, from 1989 to 2009 indicated that 9 (2%)
out of 662 persons had detectable RSTV-speciﬁc IgG
antibodies (Rollin et al. 1999; WHO 2009; Miranda &
Miranda 2011).
In the Philippines, during 2008–2009, serum samples were collected from 141 wild-caught bats (17 species) and at different locations 7 out of 16 serum
samples from Rousettus amplexicaudatus bats had antiRESTV antibodies. These antibody-positive bats were
captured near the RESTV positive cynomolgus monkeys and swine suggesting that bats are a possible natural reservoir of RESTV (Taniguchi et al. 2011). In the
Philippines, between July 2007 and June 2008, there
were multiple outbreaks of a respiratory and abortion
disease syndrome in swine. The clinical signs resembled an infection caused by a highly pathogenic porcine reproductive and respiratory syndrome virus
(PRRSV – an arterivirus), also referred to as ‘blue ear disease.’ The diagnostic investigation carried out at two
USA laboratories (APHIS and FADDL), revealed concomitant infection of pigs with PRRSV and RESTV. Viral
genomes from three samples revealed a very high
inter-isolate divergence (3.93%) as compared to the
original 1989 RESTV (2.5%). Anti-RESTV antibodies
could be detected in 6 out of 141 people who worked
on pig farms or with swine products (WHO 2009; Barrette et al. 2009).
In a multi-institutional study on bats in the Philippines, RESTV RNA was detected in oropharyngeal
swabs taken from Miniopterus schreibersii, and
sequencing of three samples showed high nucleotide
identity with a pig isolate from Bulacan province. Also,
four sera showed the presence of anti-EBOV antibodies, i.e. three from Acerodon jubatus, and one from Pteropus vampyrus (possibly infected with EBOV and
RESTV), also suggesting that bats could be a natural
reservoir for RESTV (Jayme et al. 2015).
In China, between February and September 2011,
137 PRRSV conﬁrmed pig spleen samples were
screened for the presence of RESTV, and four samples
were found positive. The partial sequencing of L gene
from four samples showed 95.1%–97.2% nucleotide
identities with each other and 96.1%–98.9% identity
with two RESTV variants of domestic pigs and cynomolgus macaques from the Philippines (Pan et al.
2014).
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2.2.4. Ta€ı Forest ebolavirus (Ta€ı Forest virus –
TAFV) and Bundibugyo ebolavirus (Bundibugyo
virus – BDBV)
There was a single non-fatal human case of Ta€ı Forest
^te d'Ivoire ebolavirus (TAFV – previously known as Co
virus). In 1994, a Swiss ethnologist became infected by
TAFV after conducting an autopsy examination on a
wild chimpanzee in the Ta€ı Forest, Cote-d'Ivoire (Le
Guenno et al. 1995).
The ﬁrst outbreak of VHF due to Bundibugyo virus –
BDBV (Bundibugyo ebolavirus) occurred in Uganda
between August and December 2007 and infested 131
cases with 42 deaths (CFR 32%) (MacNeil et al. 2011).
The entire genome sequencing of BDBV and the TAFV
were carried out by the Next Generation Sequencing,
and the analysis revealed that the BDBV differs signiﬁcantly from the other four Ebola virus species (Towner
et al. 2008). Another outbreak of BDBV occurred in Isiro,
DRC between June and November 2012 with 36 cases
with 13 deaths (CFR 36%). The full genome sequence
analysis revealed that the new BDBV was »98.6% identical to those of the original BDBV-2007 isolate
~o et al. 2013).
(Albarin
Human outbreaks of EVD are hypothesized to be
originated from direct contact with an infected animal
or its body ﬂuids. The human-to-human transmission
occurred through the direct contact with blood from
infected patients or other body ﬂuids (Report of an
International Commission 1978; Baron et al. 1983; Dowell et al. 1999; Muyembe-Tamfum et al. 1999; Roels
et al. 1999; Francesconi et al. 2003; Muyembe-Tamfum
et al. 2012; Lawrence et al. 2017). The major risk factors
associated with virus transmission chains are gathering
funerals of Ebola positive patients, close contact with
family members of infected patients, and treating
patients without adequate personal protective measures (Okware et al. 2002). People visiting or taking care
of infected persons are at high risk of Ebola infections
(Muyembe-Tamfum et al. 2012). Recently, a post-recovery sexual transmission of EBOV via semen has been
documented in the West African outbreak (Mate et al.
2015). Food can contribute to EBOV transmission, particularly through harvesting of bush meat (meat of
wildlife) (Mann et al. 2015). Transmission through
fomites in a clinical setting is unlikely (Bausch et al.
2007). The experimental aerosol transmission has been
demonstrated between monkeys (Jaxx et al. 1995;
Johnson et al. 1995; Reed et al. 2011) and from pigs to
monkeys (Weingartl et al. 2012). Similarly, airborne
transmission among humans is hypothetical (Baron
et al. 1983; Dowell et al. 1999).

3. Host range, carriers, and reservoirs
EBOV causes acute hemorrhagic fever in human and
non-human primates like cynomolgus (Macaca fascicularis) and rhesus monkeys (Macaca rhesus), African

green monkey (Cercopithecus aethiops) and baboons
(Papio hamadryas). Inoculation of infected material to
laboratory animals had resulted in non-lethal febrile
disease, and subsequent passages of splenic material
in animals increase the virulence leading to the death
of laboratory animals. Among mice, the newborn is
more sensitive than adult ones. Stray dogs in Africa
eating animals died due to EBOV remained asymptomatic. Furthermore, a survey in 2005 showed that around
30% of dogs had seropositivity for EBOV without any
clinical signs (Allela et al. 2005; Osterholm et al. 2015).
Pigs have been shown to acquire natural EBOV infection and can transmit EBOV to humans (Osterholm
et al. 2015) and hence alarming the food safety and
animal health ofﬁcials (Feldmann & Feldmann 2014).
However, limited information is available to predict or
prove the role of other livestock species, like cattle,
horse, sheep, etc. being a reservoir of EBOV (Mann
et al. 2015). Apart from the transmission of the virus
from reservoir animals, contaminated plant food products may also act as a source of infection to the susceptible population (Mann et al. 2015).
Researchers predict that there may be a reservoir
host for EVD, as it has a re-emerging pattern and
hypothesize that three fruit bat species, namely Epomops franqueti, Hypsignathus monstrosus, and Myonycteris torquata are the important reservoir (Leroy et al.
2009). The African fruit bats have been suggested to
be the natural reservoirs for EBOV (Zaire) and Marburg
virus (Leroy et al. 2005; Barrette et al. 2009; Pourrut
et al. 2009). In the Philippines, anti-RESTV antibody
could be detected from bats which were captured near
to the area where RESTV infections in cynomolgus
monkeys and swine had been detected, suggesting
that bats could be the possible natural reservoir (Taniguchi et al. 2011; Jayme et al. 2015). Finding of EBOV
antibodies in bats from Bangladesh increased the speculation of the bat as a reservoir (Olival et al. 2013). In
humans, there is no age and sex difference in susceptibility to EVD, and additionally, there is no report about
humans to act as a reservoir. Recently, a study conducted to ﬁnd any difference in the disease pathology
between male and female man showed both had similar risk rate, yet females have higher survival rate after
developing the disease (Team 2016). The virus can persist in the semen of men for a period of several months
(»18 months) after recovery and can be transmitted to
the female (Heeney 2015; Mackay & Arden 2015;
Bausch and Crozier 2016; Fallah et al. 2016) which suggests that man may be a reservoir for the EBOV. To
tackle this, WHO has recommended testing of semen
by RT-PCR from EVD survivors for three months from
onset of the disease along with counseling to encourage safe sexual practices until their semen is tested
negative twice (Check 2016; Purpura et al. 2016). Death
among chimpanzees and gorillas was always interposed with outbreaks in man, dead non-human
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primate's contact, and also eating of fruit bats
(Muyembe-Tamfum et al. 2012). Direct contact with
secretions from infected persons and organ transplantation seems to be another important means of transmission. Body secretions from non-human primates
also act as a potential source of infection to man (Feldmann & Feldmann 2014). Mucous membranes seem to
be the major portal of entry of the organism. Aerosol
infection in non-human primates raises concern about
the chances of airborne infection in humans (Olival
et al. 2013). Research ﬁndings show that the dried virus
particle can travel longer distance compared to the
virus in ﬂuid form. EBOV needs a liquid medium for its
survival. Hence, its transmission cannot be airborne.
Studies reported that due to the increase in population
and also increased movement of man and animals
there is difference in the disease dynamics of recent
outbreaks of EVD as compared to earlier outbreaks
(Pigott et al. 2014).

3.1. Role of animals in transmission of EBOVs
The possible source and mode of transmission of EBOV
for each outbreak are described earlier in the section
on epidemiology. In this section, the role of animals in
the transmission of EBOV is highlighted. Regarding the
multiple outbreaks of EBOV between 2001 and 2003 in
Gabon and RC, there is a link to handling/eating of
bush meat. The majority of outbreaks started with the
history of handling of infected wild animal carcasses,
including gorillas, chimpanzees, duikers (small antelopes), and possibly monkeys by the index cases (WHO
2003; Leroy et al. 2004).
^te d'Ivoire an
In 1994, in the Ta€ı National Park, Co
Ebola outbreak occurred among chimpanzees (Formenty, Boesch, et al. 1999), and an ethologist was
infected with TAFV while conducting a necropsy on a
wild chimpanzee (Formenty, Hatz, et al. 1999). Investigation of a 2007 EBOV outbreak suggested that the
possible source was fruit bats (Leroy et al. 2009). Since
anti-EBOV antibodies and viral RNA have been
detected in bats, there is a strong belief in the research
community that fruit bats could be a primary natural
reservoir for EBOV (Pourrut et al. 2009). In a large-scale
survey conducted at Gabon and RC between 2003 and
2008, anti-EBOV antibodies could be detected from six
bat species (Pourrut et al. 2009).
Multiple outbreaks of RESTV occurred between 1989
and 1996 in captive monkeys in the Philippines, the
United States of America, and Italy. During these outbreaks, three animal handlers developed anti-RESTV
antibodies without clinical symptoms. One became
infected during necropsy on a monkey as evidenced
by viremia and seroconversion. An additional, ﬁve
monkey handlers in the Philippines developed antiRESTV antibodies without signiﬁcant illness (Miranda &
Miranda 2011). Serological studies on animal handlers
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from monkey facilities and people with occupational
exposure to pigs in the USA, Italy, and the Philippines,
from 1989 to 2009 indicated that 9 (2%) out of 662 persons had detectable RSTV-speciﬁc IgG antibodies
(Rollin et al. 1999; WHO 2009; Miranda & Miranda
2011).
The RESTV infection was also identiﬁed in the Philippines (2007–2008) and China (2011) along with coinfection of PRRSV (Barrette et al. 2009; Pan et al. 2014).
In the Philippines, six workers in contact with infected
pigs had anti-RESTV IgG antibodies, suggesting that
pigs can transmit RESTV to humans. Transmission from
pigs may be due to direct contact with body ﬂuids and
respiratory routes (WHO 2009). Serum samples from
wild-caught bats during 2008–2009 in the Philippines
revealed anti-RESTV antibodies in R. amplexicaudatus
bats. These antibody-positive bats were captured near
to the area where REST infections were detected in
cynomolgus monkeys and swine (Taniguchi et al.
2011). In another study, RESTV RNA was detected in
oropharangeal swabs taken from Miniopterus schreibersii, and the presence of the virus had also been identiﬁed in additional sympatric taxa (Miniopetrus australis,
Cynopterus brachyotis, and Chaerephon plicata) and
additional locations (Puning Cave). Also, the presence
of anti-RESTV antibodies was conﬁrmed from Acerodon
jubatus and Pteropus vampyrus suggesting that RESTV
infection is widespread in bats (Jayme et al. 2015).
In a seroprevalence study conducted in the dog
population during 2001–2002 outbreaks in Gabon,
anti-EBOV virus antibodies could be detected from a
signiﬁcant number of samples which were collected
from the human outbreak area. However, antibodies
were detected in 2 out of 102 dog samples which were
collected from the non-exposed country (Allela et al.
2005). Neither Ebola-like illness nor virus could be identiﬁed from dogs, and the validity of the immune assay
for canine samples has been questioned (Osterholm
et al. 2015). During ecological studies in the CAR in
1998, EBOV RNA could be detected from mice (Mus
setulosus and Praomys spp.) and a shrew (Sylvisorex
ollula) (Morvan et al. 1999).

3.2. Role of plants and food materials in
transmission of EBOVs
Apart from the transmission of the virus from reservoir
animals and contaminated meat, plant food products
may also act as a source of infection to the susceptible
population (Mann et al. 2015). A two-year-old child was
identiﬁed as index case who was playing with mangoes partially eaten and dropped by bats (Coen &
Henk, 2015; Mann et al. 2015). There are also reports of
cases of Ebola infection and diseases acquired by eating fruits half-eaten by bats (Leroy et al. 2007). This
may be due to the shedding of virus in the saliva of
bats (Amman et al. 2015). It is evident from the study
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conducted in which plants experimentally inoculated
with the virus supported the replication of virus with
or without the development of visible lesions (Swanepoel et al. 1996; Okware et al. 2002). The ﬁrst victim of
2007 outbreak in the DRC was known to purchase fresh
bat meat before developing the disease (Mann et al.
2015). But contradictory opinion occurs regarding the
role of bushmeat as a source of infection (Mufunda
et al. 2016). There is only indirect evidence available in
this regard, and more needs to be investigated to conﬁrm whether plants, plant products, and other food
material can contribute towards spreading the disease.
If this is so, then it is a serious concern as it would
make the disease control more difﬁcult. Furthermore,
there is also fear that it might act as a weapon for bioterrorism (Maras & Miranda 2016). Capacity to transmit
the infection through food products depends on the
ability of the virus to survive in the atmosphere for a
certain period. It has been found that EBOV can survive
up to a period of three weeks at a lower temperature
in the atmosphere (Piercy et al. 2010).

4. Ebola virus disease (EVD)
EVD has an acute clinical outcome with signs like nausea, vomiting, diarrhea, pain in the abdomen, muscles,

and head; there is also the loss of appetite and enlargement of lymph nodes (Olival et al. 2013; Feldmann &
Feldmann 2014). The incubation period ranges from 1
to 10 days, while exceptions may reach up to 21 days.
Hemorrhages and sudden rise in temperature are the
two common clinical signs noticed and other signs of
chest pain, difﬁculty in breathing and swallowing.
Blood may be noticed in feces and urine; there may
also be coagulation problem during bruises or damage
to blood vessels (Jahromi & Mood 2015). Bleeding
from nostrils, gums, vaginal mucosa, and gastrointestinal (GI) tract have been a common sign in 40%–50% of
the cases, and maculopapular rashes can be noticed in
50% of cases. Bleeding begins within seven days from
the start of initial clinical symptoms, and it may be
noticed both internally as well as subcutaneously.
Hemorrhages may range from petechiae, purpura, and
ecchymoses; hematomas can also occur due to bleeding in the subcutaneous tissue. Death can occur within
7–16 days from the start of clinical symptoms and
occurs due to several organ dysfunctions and severe
bleeding (Takada & Kawaoka 2001; Hoenen et al.
2006). Patients who survive from EVD will exhibit organ
swelling, orchitis, and pain in the joints. An overview of
EBOV transmission, pathogenesis, and clinical signs is
depicted in Figure 5.

Figure 5. Transmission, pathogenesis, and clinical signs of Ebola virus.
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The major route of infection is through the mucosa
or skin from where it reaches the macrophages, monocytes, and dendritic cells, leading to spread of the virus
to regional lymph nodes, liver, and spleen. Macrophages and monocytes stimulated by EBOV release
cytokine storm thereby damaging tissues and blood
vessels (Olival et al. 2013). Death occurs due to blood
loss and/or coagulation (Casillas et al. 2003). Coagulopathy occurs due to thrombocytopenia, loss of anticoagulant protein C, destruction of clotting factors, and also
due to the destruction of ﬁbrin. Damage to blood vessels causes disseminated intravascular coagulation as
well as renal failure (Geisbert et al. 2003a; Nyamathi
et al. 2003). Antibodies developed against EBOV bind
with the complement C1q and reach to the binding
sites on dendritic cells and macrophages, leading to
damage of these cells.
Lesions of EVD include extensive hemorrhages of
the mucosa, necrosis of different organs like liver, kidney, testes, and ovaries. Necrotic foci with inﬂammatory cells can be noticed in hepatic lobules, and there
may be multinucleated syncytia formation in the
hepatic cells. Necrosis of red pulp and ﬁbrin deposition
are the characteristic lesions noticed in the spleen.
Splenic macrophages reveal big, acidophilic particles
in their cytoplasm which are similar to intracytoplasmic
inclusion bodies. GI tract shows mononuclear inﬁltration into the submucosa and lamina propria. Mild
emphysema, edema in the terminal alveoli, and stasis
of blood can be noticed in the lung parenchyma
(Wyers et al. 1999).
The clinical features observed in different EBOV and
SUDV outbreaks were almost similar. The disease
caused by EBOV and SUDV is known as ‘Ebola virus disease’ (EVD) – the term ‘Ebola hemorrhagic fever’ (EHF)
was previously used. In EBOV outbreak in Zaire in 1976,
the major clinical manifestations observed included a
severe sore throat, maculopapular rash, intractable
abdominal pain, and bleeding from multiple sites principally the gastrointestinal tract (malena, haematemesis, mouth/gingival, vaginal epistaxis, injection sites/
scariﬁcation) (Report of an International Commission
1978). More detailed clinical manifestations were
reported in SUDV outbreaks in Sudan in 1976. In this
outbreak, EHF was a unique clinical disease with a CFR
(53%) and a prolonged recovery period in those who
survived. The clinical signs observed were fever, headache, and pains in joint and muscle, diarrhea, vomiting,
chest pain, pain and dryness of the throat, rash, and
hemorrhages (Report of a WHO/International Study
Team 1978). In contrast to the above outbreaks, clinical
manifestations observed in 2013–2016 West African
outbreaks differed mainly due to less hemorrhage (less
than 5% of patients before death). There were four clinical phases: (1) an early febrile phase (onset 0–3 days) –
fever (up to 40  C), malaise, fatigue, body aches etc., (2)
gastrointestinal phase (onset 3–10 days) – epigastric
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pain, nausea, vomiting, diarrhea, persistent fever,
asthenia, headache, conjunctival injection, chest pain,
abdominal pain, arthralgias, myalgias, hiccups, delirium
etc., (3) shock or recovery phase (onset 7–12 days)
diminished consciousness or coma, rapid thready
pulse, oliguria, anuria and tachypnea, and (4) late complications phase (onset 10 days) associated with gastrointestinal hemorrhage, secondary infections,
meningoencephalitis, and persistent neurocognitive
abnormalities (Chertow et al. 2014; Chertow et al.
2016). The convalescent state is complicated by uveitis
and viral shedding through ocular discharge (Varkey
et al. 2015; Chancellor et al. 2016). In a study conducted
by the WHO on EVD in West Africa, the most common
symptoms observed included fever, fatigue, vomition,
diarrhea, loss of appetite, headache, abdominal pain,
and hemorrhagic symptoms (WHO Ebola Response
Team 2014, 2016).

5. Post-Ebola syndrome
Of note, thousands of patients have survived during
the Ebola outbreaks and have shown symptoms that
persisted or developed after hospital discharge, which
could be due to the persistence of the virus in the
immune privileged sites, such as brain and retina of
the host (Fallah et al. 2016). Defective interfering particles of the virus might be responsible for virus persistence and chronic condition due to EBOV infection as
observed under in vitro condition in cell culture condition (Calain et al. 2016). To note, this virus persists in
the body longer than suspected by the scientists. However, there is a paucity of sequelae of data regarding
post-Ebola syndrome (PES). In an SUDV outbreak in
Uganda in 2000, 60 out of 257 people survived and the
PES complications observed included abdominal pain,
loss of vision and hearing, impotence, bleeding, psychological problems, and general weakness (Wendo
2001; Shantha et al. 2016). During 1995 EBOV outbreak
in Kikwit DRC, the clinical signs observed among 19
survivors were arthralgia, ocular disease, parotitis, unilateral orchitis, hearing loss or tinnitus, and pericarditis
(Kibadi et al. 1999). In the same outbreak, 29 Ebola convalescents and 152 household contacts (HHCs) were
monitored for up to 21 months. Arthralgias and myalgia were the most commonly reported symptoms
among convalescents. The other clinical signs
observed during the ﬁrst six months of follow-up were
abdominal pain, extreme fatigue, and anorexia more
frequently than did HHCs, whereas fever, headache,
diarrhea, dyspnea, hiccups, and hemorrhage were the
same in both groups (Figure 5) (Rowe et al. 1999).
In a recent outbreak occurred in Guniea in 2015, a
survey was conducted on 105 EVD survivors using a
standard data collection form revealing anorexia and
arthralgia frequently (Qureshi et al. 2015). Other clinical
signs reported in different outbreaks included pain,
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weakness, hearing difﬁculty, and mental disturbances
(Report of a WHO/International Study Team 1978;
Okware et al. 2002). Recently, a very systematic crosssectional survey of the symptoms of all survivors was
conducted from the Ebola Treatment Unit at Freetown,
Sierra Leone. The unit treated 88 EVD conﬁrmed cases
between 1 December 2014 and 31 March 2015, of
whom 44 survived. The symptoms observed in the survivors included musculoskeletal pain (70%), headache
(48%), and ocular problems (14%). A total of 117 separate complaints were reported, 31 patients (70%) had
musculoskeletal pain, 21 (48%) had headaches, and 6
(14%) had ocular problems. Twenty-six (59%) of the 44
survivors reported other symptoms like cough, abdominal pain, chest pain, itching, insomnia, fever, loss of
appetite, labored speech, epigastric pain, rash, weight
loss, hiccups, increased appetite, chest pain, sneezing,
diarrhea, vomiting, left sided weakness with facial
nerve palsy, breathlessness, rash, dry ﬂaky skin, earache, fever blister/cold sore, left scrotal swelling, nasal
congestion, and tremors (Scott et al. 2016).

6. Pathogenesis
The EBOV viral proteins are involved in various stages
of the pathogenesis (Figure 5), namely VP35 is essential
for ribonucleoprotein complex (RNP) production,
important for viral replication and transcription, and
VP35 blocks the signaling of type I interferon (Muhlberger et al. 1999; Basler et al. 2000; Basler et al. 2003).
By antagonizing the production of interferon, host cellular IFN-a/b response obstruction and inhibition of
anti-viral protein production as a result of dsRNA of the
virus are the mechanisms involved in pathogenesis
caused by VP35 protein (Basler et al. 2003; Wong et al.
2014). VP40 matrix protein is involved in budding from
the host cell and also involved in the formation of the
virus-like particles (VLPs) (Harty et al. 2000; Jasenosky
et al. 2001; Noda et al. 2002). Envelope GP and other
viral proteins may have a role to inhibit immune mechanism thereby increasing the virulence of the virus
(Takada & Kawaoka 2001). Lately, scientists have tried
to elucidate the exact molecular pathogenesis of this
virus (Shi & Shen 2013) where they found that caspase
8, FADD like apoptosis regulator (CFLAR), dystroglycan
1 (DAG1), and tissue factor pathway inhibitor were
inhibited in human umbilical vein endothelial cells
expressing EBOV GP.
The virus enters through mucosal surfaces, cut or
lesions of the skin, or direct transfer. Cells like monocytes, macrophages, dendritic cells, hepatocytes, and
endothelial cells are the targets of EBOV (Feldmann
et al. 1996; El Sayed et al. 2016). Epithelial, endothelial
ﬁbroblasts, hepatocytes, and adrenal gland cells are
also infected (Olejnik et al. 2011). Following infection,
mononucleated cells are preferred by EBOV for replication in initial stages and a rapid viremia is generated

(Olejnik et al. 2011). EBOV destructs lymphocytes and
monocytes and induces cytokine storm and coagulation anomalies. Also enhanced activation of B and T
cell is evident with a higher magnitude of inﬂammatory cytokines (McElroy et al. 2015). Evidence suggests
the pathological manifestations by EBOV via releasing
immune mediators which are more critical. There is a
rapid multiplication of virus inside the host, and it
escapes the host defense mechanism. A major target
of EBOV is antigen presenting cells mainly CD16+
monocytes which are not activated in an acute episode
of EVD (L€
udtke et al. 2016). Both virus-encoded and
host proteins are responsible for pathogenesis, releasing inﬂammatory cytokines like tumor necrosis factor
alpha (TNF-a), IFN-a, IFN-g, interleukin-2 (IL-2), and IL10 that are responsible for massive hemorrhage and
death (Villinger et al. 1999). This strongly activates the
immune system, and mainly interferon-related genes
are upregulated (such as ISG15, OAS1, etc.) (Caballero
et al. 2016). Antibodies can be detected after six days’
post infection and can be detected up to 90 days.
Reports show that IgG response can be detected for
around 400 days in animals while it can persist around
10 years in human sera (Ksiazek, Rollin, et al. 1999).
Though antibodies can be detected in the serum
against glycoproteins, they turned out to be not protective against infection and also failed to inhibit replication of the virus in cell culture. Passive
administration of antibodies to animals prevented clinical manifestations but has not prevented death which
hypothesizes that immunity is not mainly through antibodies but could also be cell-mediated. There is no
report till to date regarding the re-infection of EBOV in
a person who suffered earlier infection, showing that
there is lifelong immunity against EBOV.
During the clinical course, the predominant clinicopathological ﬁndings included hypoalbuminemia,
hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia. Aminotransferase activity peaked at a
median of nine days after the onset of illness (Uyeki
et al. 2016).

7. Experimental animal inoculation
Several experimental studies have been conducted on
the animal-to-animal EBOV transmission using different animal species. One of the studies demonstrated
transmission of EBOV from inoculated rhesus monkeys
to control monkeys caged in the same room. They postulate the possible mode of transmission through aerosol, oral, or conjunctival exposure to virus-laden
droplets (Jaax et al. 1995). However, there is a possibility for transmission through spitting and throwing
feces by the monkeys (http://www.cdc.gov/vhf/ebola/
transmission/human-transmission.html) or through
routine animal husbandry practices (Osterholm et al.
2015). In another study, the transmission of EBOV from
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infected pigs to uninoculated caged macaques was
demonstrated when they were housed together (Weingartl et al. 2012). The route of inoculation also might
play an important role in the transmission as in an
experiment when monkeys were inoculated with EBOV
via intramuscular route; no transmission occurred in
uninoculated control monkeys (Alimonti et al. 2014).
Few studies have examined the role of route of
exposures in transmission. One such study demonstrates that EBOV infection through oral, conjunctival,
or intramuscular routes can cause the illness in rhesus
monkeys (Jaax et al. 1996). In another study, aerogenic
route of infection was demonstrated with different
doses of antigen (Johnson et al. 1995). Another study
investigated the replication, pathogenicity, shedding,
and transmission efﬁcacy of EBOV in pigs, wherein, following mucosal exposure, EBOV replicated in pigs,
mainly in the respiratory tract, and induced severe
lung lesions (Kobinger et al. 2011).

8. Clinical and laboratory diagnosis: a complex
issue!
During several Ebola outbreaks since 1976, EVD has
emerged as a direct challenge to manage (CDC 2015;
Mattia et al. 2016; Racsa et al. 2016). If detected early, it
gives good prognosis and lives can be saved (Okware
et al. 2015). The diagnostic and therapeutic advances
following the most recent outbreak have improved
prognosis to some extent (Butler 2014; Gilbert 2015). In
a September 2014 statement, the WHO said:
The Ebola epidemic ravaging parts of West Africa is the
most severe acute public health emergency seen in
modern times. Never before in recorded history has a
biosafety level four pathogen infected so many people
so quickly, over such a broad geographical area, for so
long. (WHO 2014)

This grim situation triggered a search for reliable
and sensitive laboratory tests to identify Ebola and
diagnose EVD as early as possible after exposure (Ayukekbong 2016; Uyeki et al. 2016). Historically, Dr Ngoy
Mushola recorded the ﬁrst clinical description of the
EVD in his clinical log during the Zaire outbreak: ‘The
illness is characterized by a high temperature of about
39  C, hematemesis, diarrhea with blood, retrosternal
abdominal pain, prostration with “heavy” articulations,
and rapid evolution of death after a mean of three
days’ (Olupot-Olupot 2015; Shah et al. 2015). At present
WHO/CDC deﬁnes that:
any illness with onset of fever and no response to
treatment for the usual causes of fever in the area,
along with at least one of the following signs: bloody
diarrhea, bleeding from gums, bleeding into skin (purpura), and bleeding into the eyes and urine

for a suspected Ebola case.
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To proceed for diagnosis, ﬁrst of all, patients’ history
such as travel, occupation, and exposure to wild animals must be recorded. The most difﬁcult task in EVD
exposure is to speciﬁcally and differentially diagnose
the EVD at the onset of disease symptoms. The EVDinfected individuals are presented clinically as very sick
with muscular and abdominal pain, cramps and hiccups with vomition and diarrhea, severe headache,
weakness followed by bruising and petechial bleeding.
With the severity of disease, mucosal and frank bleeding occurs in the form of epistaxis and bloody stool.
The EVD symptoms are quite similar with several other
infectious diseases such as Typhoid fever, Lassa fever,
Meningococcemia, Malaria, Inﬂuenza, Measles, Marburg virus disease, Shigellosis, Leptospirosis, Yellow
fever, fulminant viral Hepatitis, and Travelers’ diarrhea
(Hartman et al. 2010; Uyeki et al. 2016) and thus need
to be differentially diagnosed. The CDC/WHO recommend for immediate clinical risk analysis for EBOV
infection in any person with the symptoms described
above. Currently, there is no speciﬁc treatment existing
except that an early diagnosis of EBOV will ensure fast
supportive care before the development of irreversible
shock and necessary preventive measures and patient
isolation can be instituted. Since major Ebola outbreak
in 2014, researchers are tirelessly working to develop a
speciﬁc test to conﬁrm Ebola exposure before and after
the onset of clinical symptoms. This initiative is also
critical as most of the body ﬂuids are highly infectious
due to the persistent presence of Ebola for a long time.
The abrasions on the skin and exposed mucosa are the
most likely route of infection after direct contact of
EBOV-containing body ﬂuids from an infected person.
The WHO/CDC characterized blood, feces, and vomit
as the most infectious body ﬂuids. Furthermore, EBOV
also been detected in saliva (Formenty et al. 2006;
Spengler et al. 2015), breast milk (Nordenstedt et al.
2016), aqueous humor (Varkey et al. 2015), semen, vaginal ﬂuid, and urine (Deen et al. 2015; Chughtai et al.
2016; Fischer et al. 2016; Pettitt et al. 2016; Thorson
et al. 2016).
After the EVD-outbreak in 2014, there is a critical
urgency for the availability of robust diagnostic and
prognostic tools for infectious diseases, particularly, in
the resource-poor areas (Ghani et al. 2015). Diagnostic
measures must be employed as soon as clinical symptoms become evident. In the early stage of infection,
the presence of EBOV-antigen must be conﬁrmed, followed by antibody detection at the late stage of infection (Olival et al. 2013; Okeke et al. 2014). In the year
1979, the ﬁrst report on the quantitative measurement
of antibodies against EBOV in human sera from Northwest Zaire was published (Van der Groen & Pattyn
1979). Subsequently, an immunoﬂuorescence focus
assay (Truant et al. 1983) and formalin-ﬁxed tissue
specimens by enzyme treatment (Kurata et al. 1983)
were developed to detect EBOV. Since EBOV equally
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infect primates, an enzyme immunosorbent assay was
employed (Ksiazek et al. 1992) for the detection of
EBOV in the infected primate tissues. For rapid diagnosis (within 30 minutes), EBOV-antigen detection based
on the immune-ﬁltration technique was also developed with limited detection of the Zaire and Sudan
species only (Lucht et al. 2007). Ultimately, the conﬁrmatory diagnosis relies on the isolation of virus on
Vero or Vero E6 cell lines (Steele et al. 2001; Sanchez
2007; Makino & Kawaoka 2009). However, handling of
infected samples and isolation of virus essentially
requires BSL 4 infrastructure due to very high infectivity and mortality of lab personel. Various other diagnostic platforms include electron microscopy,
immunohistochemistry, and IgG and IgM antigen capture enzyme-linked immunosorbent assay (ELISA) has
also been evaluated (Mishra 2014). Serum, plasma, and
whole blood have been used with good results for
detection of EBOV using antigen capture ELISA by
using a semi-synthetic repertoire of llama singledomain antibodies (Sherwood et al. 2007).
RT-PCR seems to be a good diagnostic tool for
detection of the virus (Drosten et al. 2002; Towner
et al. 2004). Given the complex nature of EVD and rapid
transmission, it is essential to deploy highly sensitive
and speciﬁc EBOV detection assays. A reverse transcription loop-mediated isothermal ampliﬁcation (RT-LAMP)
has been developed to detect EBOV within 26 minutes
(Kurosaki et al. 2007) without RT-PCR instruments.
Recently, RT-LAMP for detecting EBOV directly from
blood has been described for the GP gene of EBOV. It
detects EBOV within 40 minutes with high sensitivity of
detection limit to identify 2.8 £ 102 pfu/test and 1 £
103 pfu/test of EBOV-Kikwit and EBOV-Makona, respectively (Benzine et al. 2016). Further, using DNA-intercalating dye SYBR green based or TaqMan probe-based
real-time RT-PCR, highly sensitive detection of EBOVantigen is possible (Huang et al. 2012; Liu et al. 2012).
A multiplex real-time PCR has also been developed to
detect Ebola and Marburg viruses in a single step
(Yang et al. 2012). Similarly, several companies around
the world are marketing lateral ﬂow-like kits that can
detect EBOV-antigens. Corgenix (Broomﬁeld, CO, USA)
and Veda Lab (Alenson, France) have developed kits
which use a small amount of sample (blood, plasma, or
urine) from infected persons (Baker 2014).
ELISA tests can be used for detection of antibodies
of EBOV though this is not promising as antibodies
develop only in the late phase of the infection and a
chance for a person to escape the initial phase without
death is less (Ksiazek, West, et al. 1999; Mishra 2014).
Similarly, there is cross-reaction of antibodies with
other pathogens. Therefore, antibody detection tests
are less effective for EBOV infection. Speciﬁc detection
of EBOV in clinical laboratories is currently being carried out largely through the analysis of the virus's
nucleic acid (genetic material), using commercial or in-

house tests (Dhama, Malik, et al. 2015). Although these
nucleic acid tests (NATs) are highly speciﬁc they require
well-established laboratories and fully trained personnel due to their complex nature. Also, the turn-around
time of the ﬁnal results may take more than 12–
24 hours. During Guinea Ebola outbreak, patient's
swab samples were used to detect EBOV by a rapid
reverse transcription recombinase polymerase ampliﬁcation (RPA) assay (EBOV-RT-RPA). This highly efﬁcient
assay produced results in 30–60 minutes (Faye et al.
2015; Dedkov et al. 2016). A new test comparable to
ELISA is developed by using Fe3O4 magnetic nanoparticle as a nanozyme probe (nanozyme-strip) to speciﬁcally detect the EBOV-glycoprotein as low as 1 ng/mL
and is 100-fold more sensitive than the standard strip
method (Duan et al. 2015). The WHO/CDC has ofﬁcially
approved (19 February 2015) the *ReEBOVTM Antigen
Rapid Test Kit (Corgenix, Broomﬁeld, CO, USA) as eligible for procurement and to be used in Ebola-affected
countries (Dhillon et al. 2015; Flint et al. 2015). The
ReEBOVTM Antigen Rapid Test is an immune-chromatographic dipstick immunoassay point-of-care test
based on detection of the Ebola protein (VP40 antigen)
rather than nucleic acid and can provide results within
15 minutes. The ReEBOVTM Antigen Rapid Test kit can
correctly identify about 92% of Ebola-infected patients
and 85% of those not infected with the virus compared
to other available NAT and currently being used in the
ﬁeld (RealStar® Filovirus Screen RT-PCR Kit 1.0, Altona
Diagnostics GmbH, Hamburg, Germany). Despite the
fact that ReEBOVTM Antigen Rapid Test kit is less accurate, it is easy to perform and does not require electricity. It can, therefore, be used at lower health care
facilities or in mobile units for patients in remote areas
(Broadhurst et al. 2015). It is always better to conﬁrm
the data from ReEBOVTM Antigen Rapid Test Kit by testing a new blood sample using an approved Ebola NAT.
To test the sensitivity and versatility, comparative studies on 11 different procedures have been performed
for currently available RT-PCR assays (Nouvellet et al.
2015; Cherpillod et al. 2016). However, the detection
limit of ReEBOVTM test is not sufﬁciently sensitive to
identify all the EVOB-suspected cases. Another signiﬁcant obstacle to the use of these RT-PCR tests is to
detect novel ﬁlovirus species and lineages which have
emerged due to rapid mutation rates and genetic
diversity of RNA viruses. More recently, a real-time RTPCR assay was developed as a point-of-care test that
does not require RNA extraction and thus the entire
process completes within 1.5 hours (Zhang et al. 2017).
The chronology of diagnostic tests developed to
detect EBOV in various situations has been summarized in Table 3 and the diagnostic kits developed for
EBOV detection are presented in Table 4.
In recent times, new nucleic acid sequencing technologies (referred to as ‘next-generation’ sequencing
(NGS) have evolved which provide more efﬁcient and
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Table 3. Chronology of Ebola diagnosis efforts.
S.
No.
(1)

Technique(s)
Formalin-ﬁxed tissue-specimens
examination after enzyme
treatment.

(2)

Immunoﬂuorescence focus assay.

(3)

Enzyme immunosorbent assay for
primates.
Immuno-enzyme test system.

(4)
(5)

Transmission electron microscopic
study of the hemorrhagic spots.

(6)

Immuno-histochemical and
electron microscopic
examination techniques.
Diagnosis by RT-PCR in an
epidemic setting.

(7)
(8)

Development and evaluation of a
ﬂuorogenic 5' nuclease assay.

(9)

5' nuclease probe detection by
real-time reverse transcriptionPCR.
Antigen capture ELISA directed
against the envelope
glycoprotein of Ebola virus.
Rapid diagnosis of Ebola
hemorrhagic fever by reverse
transcription-PCR in an outbreak
setting and assessment of
patient viral load as a predictor
of outcome.
Immune-ﬁltration based antigendetection assay for rapid
detection (only Zaire and Sudan
strain-speciﬁc).
Reverse transcription-loopmediated isothermal
ampliﬁcation assay (Zaire strainspeciﬁc).

Input molecule (starting
material)
Formalin-ﬁxed tissue
–
slides

Target to be used for
detection

Advantage(s)
Advantages are minimized due
to arrival of sophisticated and
efﬁcient diagnostic
techniques.

Serum

Ebola antigen

Squamous epithelial
cells and the capillary
endothelial cells on
mucous membrane of
mucous membrane of
soft palate
Tissue

Direct virus visualization

Visualization of virus in the
enlarged Golgi apparatus.

Viral antigens and particles
directly visualized

For safe, sensitive, and speciﬁc
detection of Ebola virus in
formalin-ﬁxed skin.
PCR-based diagnostic assay.

Peripheral blood
mononuclear cells
(PBMC)
Cultured virus in Vero
cells

Nucleic acid

Serum

Nucleic acid

Serum

Glycoprotein (GP) antigens

Serum, blood, or plasma

Nucleoprotein (NP)

Serum

Glycoprotein (GP) antigens

Detect and differentiate
between Zaire and Sudan
subtypes.
Detection limit: 9–16 RNA
copies per reaction.

Reference/year
Kurata et al.
(1983)
Truant et al.
(1983)
Ksiazek et al.
(1992)
Borisevich et al.
(1996)
Wang et al.
(1997)

Zaki et al.
(1999)
Leroy et al.
(2000)
Gibb et al.
(2001)
Drosten et al.
(2002)

Sensitivity up to »103 pfu/ml.
Able to detect even SDSinactivated virus.
One-step ﬂuorogenic Q-RT-PCR
assay

Lucht et al.
(2004)

Matrix protein (VP40)

Sensitivity similar to ELISA and
rapid assay without need of
the higher technical skill.

Lucht et al.
(2007)

Vero cells cultured virus

NP

Kurosaki et al.
(2007)

(14) Quantitative 5’ nuclease assay for
NP/-

Vero cells cultured virus

NP

(15) SYBR Green I real-time RT-PCR.

Cell cultured virus

NP

Portable ampliﬁcation-based
platform.
Negative for other febrile
disease viruses such as Lassa
virus, Rift Valley fever virus,
Yellow fever virus.
Evaluation of commercial
mastermixes for sensitivity
and reaction time.
No cross reactivity with
Marburg, Dengue, Xinjiang
hemorrhagic fever virus,
Japanese encephalitis virus,
Inﬂuenza virus (H1N1 and
H3N2) and Porcine
reproductive and respiratory
syndrome viruses.
Sensitive with ability to test
two hemorrhagic viruses in a
single assay.
Very sensitive assay.

(10)
(11)

(12)

(13)

(16) Multiplex RT-PCR for simultaneous Cell cultured virus
detection of Marburg virus and
Ebola virus.
(17) Indirect ELISA for detecting Abs
Cell culture supernatant
speciﬁc to Ebola and Marburg
viruses.
(18) Novel biomarker soluble CD40
Serum
ligand (sCD40L) correlates of EVD
clinical outcome.

Nucleic acid
NP
Different 26 cytokines

(19) Comprehensive multiplex one-step Cell cultured virus
TaqMan qRT-PCR assay.

Nucleic acid

(20) Aptameric sensing technology for
rapid pandemic monitoring.

Protein

Serum

Simultaneous detection of 26
proinﬂammatory cytokines.
Increased soluble CD40
ligand (sCD40L) level is
indicator of diseases severity.
In a single qRT-PCR assay, 28
hemorrhagic viruses may be
detected.
Aptamers are bio-afﬁnity
probes with improved
pathogen detection ability.

Towner et al.
(2004)

Stephens et al.
(2010)
Liu et al. (2012,
2014)

Yang et al.
(2012)
Huang et al.
(2014)
McElroy et al.
(2014)

Pang et al.
(2014)
Acquah et al.
(2015)
(continued)
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Table 3. (Continued)
S.
Input molecule (starting
Target to be used for
No.
Technique(s)
material)
detection
(21) GeoSentinel surveillance network. General health
Patients
Differential diagnosis of illness in
surveillance of physical
travelers arriving from Sierra
illness
Leone, Liberia, or Guinea.
(22) Antigen capture ELISA and lateral
ﬂow immunodiagnostic.
(23) Optoﬂuidic analysis system for
ampliﬁcation-free, direct
detection of Ebola.
(24) Fe3O4 magnetic nanoparticlebased immuno-chromatographic
strip (Nanozyme-strip)
(25) Rapid recombinase polymerase
ampliﬁcation Ebola virus
detection assay.
(26) Real-time EBOV-L-RT-qPCR for
detection of Zaire Ebola virus.
(27) The Ebola Spatial Care PathTM
(SCP): accelerating point-of-care
testing (POCT).

(28) Ultrafast, sensitive and largevolume on-chip real-time PCR.
(29) Prototype Cepheid GeneXpert
Ebola Assay.

Serum
Serum
Serum

Advantage(s)
Based on clinical data collected
on GeoSentinel global
surveillance network
platform (57 specialized
travel and tropical medicine
clinics).
Matrix VP40 and glycoprotein Sensitivity sufﬁcient for clinical
(GP) antigens
diagnosis.
Nucleic acid
Chip-scale approach
Single nucleic acid detection
in 10 minutes.
Gycoprotein (GP) antigens
Comparable to ELISA, but faster
and simpler.

Serum and swab

Nucleic acid

Serum or blood

L gene

Whole blood

Cultured virus

Untranscribed trailer region
or nucleoprotein coding
region of the viral RNA

(31) Upconversion nanoprobe/
nanoporous membrane system.

Inactivated Ebola virus
samples

Ultrasensitive detection of
Ebola virus oligonucleotide

(32) Bioﬁre Film-Array BioThreat-E Test
(v2.5).

EDTA-blood, serum or
plasma

–

(33) Zaire Ebola virus (ZEBOV)-speciﬁc
enzyme-linked immunosorbent
assay (ELISA) using inactivated
ZEBOV isolate Makona
(34) RT-LAMP

Serum

Glycoprotein (GP) antigens

Blood

Untranscribed trailer region
or nucleoprotein coding
region of the viral RNA.

Whole blood or serum

VP antigen (anti-EBOV VP40)

(35) ReEBOV Antigen Rapid Test
(ReEBOV RDT)

speciﬁc viral diagnostics. The technology of NGS provides rapid high-throughput DNA sequence data in
large volumes. The NGS has been successfully tested
for its efﬁciency during the 2014 Ebola outbreak in
Guinea and Sierra Leone (Gire et al. 2014). This study
was able to identify the virus sequence differences and
similarities to previous outbreak variants and to elaborate its emergence from the natural reservoir. Further,
data helped the researchers to understand how EBOV
has moved across African nations during the months
of the outbreak (Gire et al. 2014). A new approach for
direct detection of EBOV infection has been tested.
This approach is ampliﬁcation-free and based on the

Boisen et al.
(2015)
Cai et al. (2015)
Duan et al.
(2015)

Assay can combine extraction
Faye et al.
and detection in a single
(2015)
step.
No false positives with serum
J€a€askel€ainen
or EDTA bloods samples.
et al. (2015)
Ebola molecular diagnostics
Kost et al.
kits for rapid POCT.
(2015)
The reader/processor/
cartridges in sealed,
disposable pouches
containing the biological and
chemical reagents.

Platelet count, white blood
cell count, granulocyte
count and percentage, and
lymphocyte/monocyte
count and percentage,
prothrombin time, virusspeciﬁc IgM and IgG,
hemoglobin and hematocrit
(General pathogen detection)
Ultrafast RT-PCR system using
microﬂuidic thermalization
can detect Ebola in 7.5
minutes.
Stored serum and
GP and NP gene
No cross-reactivity.
plasma samples
Less input sample volume.

(30) RT-loop-mediated isothermal
ampliﬁcation (RT-LAMP) assay

Reference/year
Boggild et al.
(2015)

Houssin et al.
(2016)

Pinsky et al.
(2015); Jensen
et al. (2016)
Higher sensitivity to nanoscale. Kurosaki et al.
No cross-reactivity to other
2016
hemorrhagic fever viruses
and arboviruses.
Detection up to pico-mole
Tsang et al.
level.
(2016)
Low cost, rapid, and
ultrasensitive detection.
Whole blood may be used.
Leski et al.
(2015); Weller
et al. (2016)
Simple and cost effective.
Kr€ahling et al.
(2016)

Whole blood used to detect GP
gene of EBOV
high sensitivity
Result within 40 minutes
Highly speciﬁc
Point of care test for EVD

Benzine et al.
(2016);
Kurosaki et al.
(2016)
Cross et al.
(2016)

optoﬂuidic analysis (Cai et al. 2015). Recently, a
research team from Marburg, Germany (Kr€ahling et al.
2016), has developed a Zaire Ebola virus (ZEBOV)-speciﬁc ELISA using inactivated ZEBOV-Makona virus isolate. The ZEBOV-ELISA is highly speciﬁc and sensitive
with superior reproducibility. This newly developed
test is suitable both for the detection of the ZEBOV surface glycoprotein in vaccinated individuals and for
detection of speciﬁc antibody responses directed
against different ZEBOV proteins in EVD patients
(Kr€ahling et. al. 2016). The possibility of EBOV-encoded
miRNA-like fragment as a speciﬁc biomarker for early
EVD conﬁrmation has also been explored (Chen et al.
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Table 4. Diagnostic kits developed for Ebola virus (EBOV) detection.
S.
No.
(1)
(2)
(3)
(4)

Kit name
–
ABICAP-rapid-Ebola test
AccuPower EBOV
Quantitative RT-PCR Kit
(EBO-1111A)
eZYSCREEN kit

(5)

LiferiverTM Ebola Virus
(EBOV) Real Time RT-PCR
Kit
(6) LightMix Modular Ebola
virus Zaire
(7) Lipsgene SEBOV/ZEBOV Kit
(8) OraQuick® Ebola Rapid
Antigen Test Kit
(9) Rapid Response Ebola Virus
Test Cassette
(10) RealStar Filovirus Screen
RT-PCR Kit 1.0
(11) ReEBOV Antigen Rapid Test
Kit
(12) SD Q Line Ebola Zaire Ag
(13) Xpert® Ebola Test

Type of the test
Antigen detection: LAMP
Antigen detection – antibody
immuno-column for analytical
purpose
Nucleic acid detection: RT- PCR

Input material(s)
Company name, country
Serum, plasma, amniotic, or synovial ﬂuid
Lucigen, USA
Whole blood, serum, urine, stool, tears, and saliva Senova GmbH, Germany
as well as in environmental samples such as
water, air, and soil
Serum or plasma
Bioneer, Korea

Antigen detection

Blood or serum

Real-time reverse transcription PCR

Blood, serum, plasma (non-heparin
anticoagulant)

Real-time reverse transcription PCR

Whole Blood

Real-time reverse transcription PCR
Antigen detection

Blood, serum, or plasma
Cadaveric oral ﬂuid/whole blood

Antigen-detection chromatographic Whole blood/serum/plasma
immunoassay
Real-time reverse transcription PCR EDTA plasma
Antigen detection: immunochromatographic dipstick
immunoassay
Antigen detection – lateral ﬂow
chromatographic immunoassay

Blood/serum/plasma
Blood or serum

Real-time reverse transcription PCR Whole blood EDTA or buccal swab specimens
in self-contained cartridge system
-

2016). The high potential of the recent advances in the
ﬁeld of diagnosis including molecular tools, LAMP, lateral ﬂow assay, biosensors, biochips, microarrays,
recombinant protein, and nanotechnology-based
detection methodologies must be exploited to their
full perspectives for rapid detection and monitoring of
EBOV infections (Kurosaki et al. 2007; Belak et al. 2009;
Dhama et al. 2014; Benzine et al.2016).

9. Global EBOV monitoring and disease
surveillance: did we learn new lessons?
Due to social conﬂicts, globalization and climate
change, intercontinental migration of humans has
been rampant. The uncontrolled movements and
demographic transitions demand a serious preparedness for unseen lethal epidemics of uncommon viral
diseases. It is no more an exotic infection for any country but has taken the nature of a global problem
(Arwady et al. 2015). Thus, surveillance of emerging
infectious diseases is extremely vital for the early identiﬁcation and preparedness of public health threats.
Fortunately, particularly after the 2014 outbreak, several new rapid molecular diagnostic assays have
become available for precise surveillance of highly
infectious diseases in real-time manner (Benowitz et al.
2014; Curran et al. 2016).
The last EBOV outbreak in West Africa is a serious
warning to the public health system and awakening to
the communities for better preparedness to combat
such large-scale epidemic. More than 12,000 deaths

French Atomic Energy
Commission (CEA),
France
Shanghai ZJ BioTech Co.,
Ltd., China
Tib-molbiol/Roche,
Germany
Lipsdiag, Germany
OraSure Technologies, Inc.,
USA
BTNX Inc., Canada
Altona Diagnostics,
Germany
Corgenix, USA
SD Biosensor Inc.,
GyeongGi-do, Republic
of Korea
Cepheid AB, Sweden

were reported during 2014 EBOV-epidemics. The EBOV
and related viruses are extremely lethal and managing
such diseases is beyond our capacity if not prepared
(Walker & Whitty 2015; Woolhouse et al. 2015; Jacobsen et al. 2016). New technologies have the capacity to
simulate and predict the future epidemics and can
direct the public health authorities to respond in a
swifter way to infectious outbreaks of all kinds. A multidisciplinary approach has the potential to manage the
spread of pathogens and reduce the morbidity and
mortality. These novel tools can be harnessed for
mathematical modeling, risk mapping, phylogenetic
analysis, pathogen genome sequencing, and rapid onsite diagnosis (Woolhouse et al. 2015). During 2001–
2003, a study in Gabon and RC recommended a
method for predicting and possibly prevent human
Ebola outbreaks by determining a correlation of wild
animal mortality with human Ebola outbreaks (Rouquet et al. 2005). To monitor the disease outbreak
effectively, it should be considered to gather data from
contaminated raw food products derived from bushmeat and plants also (Mann et al. 2015).
In recent times, Internet-based surveillance tools
and epidemic simulation-based prediction can efﬁciently facilitate the potential risk assessment and outbreak detection in infectious disease emergencies
which can prevent future infectious disease threats
(Christaki 2015). The widespread transmission that
occurred in the three most affected countries (Guinea,
Liberia, and Sierra Leone) in West Africa and the epidemic's designation as a ‘Public Health Emergency of
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International Concern (PHEIC)’ insisted the formulation
of speciﬁc guidelines to efﬁciently manage the EBOVepidemic. In 2014 CDC, issued interim USA guidance
for ‘Monitoring and Movement of Persons with Potential Ebola Virus Exposure’ to guide CDC staff and public
health partners engaged in the response. The guidance
provided by public health authorities and collaborative
agencies with recommendations for monitoring travelers who may be potentially exposed to Ebola and
therefore authorities can enforce the restriction in
movement. In humans, EBOV spreads through direct
contact with infected body ﬂuids (blood, vomitus,
feces, semen, vaginal ﬂuid, and urine) with broken skin
or exposed mucous membranes, and possibly through
sexual contact. Because of the risk for importing disease from infected travelers, in October 2014 the CDC
recommended that ‘all travelers to the United States of
America from Ebola-affected countries receive
enhanced entry screening and post-arrival active monitoring for Ebola signs or symptoms until 21 days after
their departure from an Ebola-affected country(CDC
2015). On 19 February 2016, the CDC-guidance expired
as Guinea was declared free of EBOV transmission
(after more than 45 days had passed since the last
EBOV case reported and the human-to-human transmission ended).
New technology platforms are now being employed
vigorously for monitoring and surveillance of EBOV
(Cross et al. 2016). During 2014 EBOV outbreak, genomic surveillance was performed using ‘next-generation’ sequencing (NGS) which helped in identifying the
EBOV origin and transmission (Gire et al. 2014). Further,
several start-ups are seriously designing the efﬁcient
and portable devices for EBOV genomic surveillance. In
this line, a novel portable Nanopore DNA sequencing
instrument (Pennisi 2016; Quick et al. 2016) was developed and used in EBOV genome sequencing. The
Nanopore real-time genomic surveillance system was
transported in standard airline luggage to Guinea and
used for real-time genomic surveillance of the ongoing
epidemic during April 2015. Once received an Ebolapositive sample, this portable system produced results
in less than 24 hours and genomic sequencing within
15–60 minutes. Such innovations warrant the use of
genomic surveillance in resource-limited settings in a
real-time manner. Rapid monitoring of potential outbreaks, using such portable sequencer, is now a reality
in remote areas (Quick et al. 2016). Further, a handy,
portable, and compact (13.5 cm £ 8.5 cm £ 2.5 cm)
infection monitoring system was recently introduced
to monitor mass gathering places such as airports (Sun
et al. 2015). This highly mobile and hand-held system
can rapidly screen the non-contact vital signs using
two integrated sensors. One sensor which is a 24-GHz
microwave radar can measure the heart and respiration rates and another sensor is a thermopile array for
capturing facial temperature. After collecting vital signs

data, the system detects infected individuals using a
linear discriminant function. Such devices can be very
useful in providing real-time updates and essential
resources for managing current Ebola outbreak with
the help of Global Ebola Response Monitoring and
Mapping System (WHO) and United Nations Mission
for Ebola Emergency Response (UNMEER) (Sun et al.
2015).
The global revolution of the Internet and social
media is a very powerful tool in disease surveillance.
Short message service (SMS)-based system has been
established to facilitate the active surveillance of individuals who are either returning from EVD-affected
countries or in contacts with EBOV-exposed local conﬁrmed cases (Tracey et al. 2015). This SMS-system collects the information on symptoms and temperature
twice daily and communicates to the public health
authorities (Tracey et al. 2015). During the August 2015
epidemic of EBOV in Sierra Leone, toll-free, nationwide
Ebola call centers were established by Sierra Leone's
Emergency Operations Center. This ‘alert’ system
proved to be very effective in providing health education about EBOV to the callers and boosting public
reporting to public health ofﬁcials about possible Ebola
cases and deaths (Miller et al. 2015). Based on a study
in southern Sierra Leone, the effectiveness of the cell
phone messaging technology has been proved to be
highly effective as a rapid communication tool for community epidemic surveillance from peripheral health
care facilities to higher levels (Jia & Mohamed 2015).
One recent report suggested that the utility of hybrid
information network in facilitating the quicker public
health measures may be possible, by integrating both
hierarchical and formalized command control-driven
and community-based, or ad hoc emerging networks,
which can efﬁciently employ social media to facilitate
the robust preparedness for the potential outbreak
and improving the capability of EBOV-identiﬁcation
and diagnosis (Hossain et al. 2016).
A community-based effort in Liberia has been very
successful to defeat the EVD in recent times (Shrivastava et al. 2016). These coordinated efforts involved
strong leadership and clear vision by the policy-maker
by declaring the disease as a public health priority to
all the concerned departments; actively involving the
community leaders by developing a sense of need
among them; increasing the level of faith and neutralizing any rumors about the disease among the local
people – by building see-through walls in treatment
centers so that people can watch the proceeding or
developing mechanism to respond promptly to transport calls or by sensitizing the health professionals to
build conﬁdence among local residents; strengthening
of the treatment facilities (by creating medical units,
treatment centers, logistics support) and laboratory
network by establishing ﬁve dedicated Ebola laboratories; courageous attitude of the local volunteers;
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enormous support from the international community;
and well-coordinated national and international
response (Shrivastava et al. 2016). In response to the
2014 EVD-outbreak, a common international code,
ICD-10-CM code ‘A98.4’ (International Classiﬁcation of
Diseases -10th Version-Clinical Modiﬁcation) has been
implemented in all – in all health care institutions for
Ebola bio-surveillance speciﬁcally. This health care coding system will facilitate real-time tracking of EBD-outbreaks (Chabra 2015). Since EBOV is a mutating RNA
virus, a rapid monitoring system using aptameric sensing technology has been proposed for pandemic surveillance (Acquah et al. 2015). Computer simulation
and mathematic modeling have been proposed to
quantify the West Africa Ebola epidemic (Chretien et al.
2015). International Society of Travel Medicine and
CDC collectively operate a global GeoSentinel surveillance network of travel and tropical medicine clinicians
that collects de-identiﬁed demographic, diagnostic,
and travel information on ill travelers who cross international borders. GeoSentinel is composed of 63 clinical sites in 29 countries on 6 continents. Through the
efforts of GeoSentinel surveillance network, differential
diagnosis of EVD in travelers arriving from Liberia,
Sierra Leone, or Guinea was conducted to track
the outbreak (Boggild et al. 2015). A similar approach
‘Surveillance and Outbreak Response Management
System (SORMAS)’ has also been suggested to support
the control of the EVD-outbreak (F€ahnrich et al. 2015).
In USA, to understand and address the doubts and
concerns of the citizens’ life twitter chat was conducted thus such platforms can be very effective in
future to collect and disseminate the information in
future at the time of such outbreaks (Lazard et al.
2015).
Finally, the lessons learned from such epidemic with
high mortality emphasize that the efﬁcient surveillance
system and coordinated global efforts involving every
social and political leader can be a best possible scenario to prevent such deadly viral disease (Carney &
Weber 2015). Though CDC/WHO has ofﬁcially declared
the end of the Ebola outbreak, the residual risks of
Ebola reintroduction or re-emergence are still haunting
the human population worldwide. According to the
Ebola Situation Report – 16 March 2016, the WHO has
strongly recommended the implementation of superior EBOV-monitoring systems in Guinea, Liberia, and
Sierra Leone to alert authorities for the EVD-clinical
cases or EVD-related death. Developed rich nations
must effectively implement a high-quality, robust
emergency response system, and provide the unconditional support to the establishment of sustainable
health care services in West Africa (Quaglio et al. 2016).
Only in this way we together can avert the next
humanitarian crisis due to EBOV or related viral
diseases.
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10. Prevention and control
Currently, there is no robust and potent vaccine to control this lethal infection leaving prevention to be the
best way to escape from infection. Monitoring, surveillance, isolating infected persons and treating them
separately, travel to the endemic area during outbreaks
should be discouraged, are the limited and effective
ways to prevent further spread of infection (Tambo
et al. 2014). For EVD-outbreak prevention, a new organization named as ‘United Nations Mission for Ebola
Emergency Response (UNMEER)’ has been created during the 2014 outbreak of EBOV in Africa.
Various strategies like reporting of EVD-outbreak,
proper treatment to infected persons, proper burial of
dead persons, disinfection of the areas, and proper
planning to prevent further spread are the measures
taken to control EVD at national and international level.
Hospitals, where infected personals are treated, should
also be disinfected along with sterilization of all instruments that come in contact with the infected persons.
Both incineration and autoclave can easily destroy the
virus. Fecal wastes should also be deactivated to
destroy the virus. Places, where there are no proper
facilities for incineration or autoclave should pack the
materials in a leak proof triple-layered container and
these should be transported to other places for sterilization and disposal.
There is an urgent need for creating awareness
among the public about this deadly disease so that
spread of Ebola can be prevented (Salman et al. 2017).
Proper monitoring at airports and public places where
there are all possible chances for spread of infection is
of utmost importance (Brown et al. 2014; Read et al.
2015). People who fall ill should be kept under the
scanner for at least 21 days to rule out the infection.
Health care workers and doctors are also at higher risks
as they come in direct contact with the infected persons. Hence, they should wear all protective wears like
gowns, gloves, face mask, goggles, and respirators and
also should follow barrier nursing. Collected samples
for diagnosis should be transported under high precaution and handled only in the BSL4 lab. Climate
change has a huge role in the dissemination of various
diseases, and EBOV can also be transmitted to nonhuman primates due to movement of bats as a result
of climate change (Dhama, Tiwari, et al. 2013). Since
bushmeat has been found to be the potential and
important source of many epidemics in the past, it is
important to monitor their illegal export to the na€ıve
countries (Mann et al. 2015).

11. Vaccines
Although EBOV was discovered in 1976 until now,
there is no effective vaccine or post-exposure
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treatment available. After the recent outbreaks, the
EVD management plan relies majorly on supportive
therapies. Since 2014 EBOV-outbreaks, the scientiﬁc
community is working tirelessly to develop immunization regimen to control virus spread (Geisbert & Jahrling 2003). The prime-boost approach of DNA vaccine
followed by adenovirus vectored ZEBOV GP has
resulted in good cellular and humoral response in cynomolgus macaques during experimental studies. DNA
vaccines are also in phase I of clinical trials. The glycoprotein of EBOV has been a good target for eliciting
humoral immunity and surface protein targeted
human monoclonal antibody has provided a ray of
hope for a better vaccine (Nyamathi et al. 2003). These
DNA vaccines contain GP and NP of any of the ﬁve
strains of EBOV. It is administered intramuscularly and
followed by booster it generated an immune response
in 70% of volunteers with poor T cell response. DNA
vaccination may be further improved by vaccinating
through electroporation, injecting higher quantities, or
prime boosting with other antigen delivery platforms
(Sarwar et al. 2015). The problem in developing a peptide-based vaccine to protect from this infection is due
to the vast similarity that exists between it and human
peptides. So, it is necessary to identify certain peptides
that are unique and conserved in EBOV to develop
peptide-based subunit vaccines (Kanduc, in press).
Experiments with lab animals like mice and guinea
pigs revealed that DNA vaccine protected them against
challenge with wild-type Mayinga 1976 strain of ZEBOV
(Gulland 2014).
Recombinant virus vectors are a good choice of
antigen delivery as they induce the cell-mediated
immune response, due to intracellular expression and
processing of antigen. Of note, Ad5 serotype is a popular adenovirus-based vector used for such purposes
due to ease in genetic manipulations and to grow to
high titers. In this approach, an E1 region of adenovirus
is replaced with GP of Ebola, and in non-human primates, it offered 100% protection in a single dose.
However, preexisting neutralizing antibodies limit the
utility of Ad vectors (Ledgerwood et al. 2010). Immunization in individuals having anti-Ad5 antibodies before
vaccination showed reduced cellular and humoral
response. Adenovirus-based vaccine (cAdVaxE) is a
bivalent vaccine against GP of ZEBOV and SEBOV
which has protected 100% of mice against challenge
(Wang et al. 2016). Another virus used include vesicular
stomatitis virus (VSV) which is an enveloped singlestranded RNA virus. The recombinant VSV is produced
by replacing GP of VSV with GP of EBOV. When recombinant VSV-based ﬁlovirus vaccine is used in primeboost approach, it can give good protection. The VSVvectored vaccine expressing GP of ﬁlovirus has protected non-human primates against three species of
ﬁlovirus and Marburg virus (Mire et al. 2013). Furthermore, it has entered in phase III efﬁcacy trial in Guinea.

It conferred protection in non-human primates using
different routes of immunization like mucosal, oral, or
intramuscular (Geisbert et al. 2009) with advantages
like transient viremia and self-limited febrile illness
(Sridhar 2015). Likewise, the recombinant human parainﬂuenza virus 3 (HPIV-3), a single-stranded, negativesense RNA virus, has been used as a vaccine candidate
owing to its ability to accommodate several GPs in the
viral backbone (Skiadopoulos et al. 2002). Intranasal
immunization with EBOV GP expressed with replication-competent HPIV3 showed better protection
against challenge with a higher parental dose of EBOV
(Yang et al. 2008). Other vectors like cytomegalovirus
(CMV)-based vaccine protected mice against EBOV,
and this has the potential to be used against EVD in
humans (Tsuda et al. 2015).
VLPs produced by expressing GP and VP40 in mammalian cells can also stimulate protective immune
response making better vaccine options (Cazares et al.
2016). GP-based fusion vaccines developed by EBOV
GP fused with Fc fragment of human IgG1 adjuvanted
with poly-ICLC have shown to induce a strong humoral
immune response and protect guinea pigs against
lethal EBOV challenge (Konduru et al. 2016). Subunit
vaccine contained GP protein expressed in Autographa
californica multicapsid nucleopolyhedrovirus, a baculovirus expression system in SF9 insect cells. Infected
cells are lysed and adjuvanted with Matrix-M, a phospholipid constituent of synthetic cholesterol and saponin. This vaccine generated higher cellular and
humoral activity (Lovgren et al. 2011; Martins et al.
2016). With the use of reverse genetics, defective EBOV
without VP30 was found 100% effective in protecting
guinea pigs and mice (Hoenen et al. 2012). Replicationdefective vaccine by deleting VP30 has also been considered as an effective vaccination strategy to prevent
the infection (Saphire 2015).
Although WHO reported two vaccine candidates,
namely chimpanzee adenovirus-based, and VSV-based
EBOV vaccines, as are under phase III clinical trials,
there is a need to search for a safe and effective vaccine (Cohen 2014; Gulland 2014). Heterologous VSVand Ad5-vectored Ebola vaccine, GamEvac-Combi was
used in phases I and II trail which induced both
humoral and cellular immunity in all the 84 volunteers
(Dolzhikova et al. 2017). Presently, seven vaccines have
entered clinical trials (Chappell & Watterson 2017). Scientists from the University of Texas, USA developed a
new EBOV inhalant vaccine that provides 67%–100%
protection in non-human primates. Most recently, a
recombinant VSV-Zaire ebolavirus vaccine (rVSVZEBOV) is being tested under ‘Sierra Leone Trial to
Introduce a Vaccine against Ebola (STRIVE)’ program.
This promising candidate vaccine, which is in phase 2/
3 human trial, is the result of collaborative efforts
between the College of Medicine and Allied Health Sciences, University of Sierra Leone, the Sierra Leone
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Ministry of Health and Sanitation, and the CDC. This
new vaccine is based on Zaire ebolavirus immunogen
and can only protect against Zaire ebolavirus, the
major agent behind EVD in West Africa (Folayan et al.
2016). Progress and advances in the area vaccines and
vaccination comprising of edible vaccine, peptide vaccine, DNA vaccine, immunomics-based vaccine, and
others need to be optimally utilized for designing and
developing effective vaccines along with exploiting
immunomodulatory approaches employing novel
adjuvants and vaccine delivery systems for improving
the efﬁcacy of the EBOV vaccines (Dhama, Wani, et al.
2013; Delany et al. 2014; Sarwar et al. 2015; Singh et al.
2015).

12. Treatment
The recommended symptomatic treatments include
anti-inﬂammatory drugs for fever and pain, and intravenous ﬂuids to maintain body osmotic balance. As
the kinome analysis revealed the involvement of mitogen-activated protein kinase (MAPK), phosphoinositide
3-kinases (PI3Ks), and calcium/calmodulin kinases in
EBOV infectivity, the PI3Ks inhibitor LY294002 and
CAMK2 inhibitor KN-93 were tested and found effective in reducing EBOV infection in Vero E6 cells. The
p38 MAP kinase has a role in activating the signaling
cascade leading to produce interleukins and TNFa. The
p38 MAPK inhibitor like SB202190 helps in ameliorating EBOV-mediated cytokine storm in human monocyte-derived dendritic cells (Johnson et al. 2014).
Artemisinin, an antimalarial drug is also beneﬁcial
regarding reducing the acute inﬂammatory response
(Ho et al. 2014). FTY720 is a drug used to treat patients
with autoimmune disorders and prevents transplant
rejection. Its sphingosine analog AAL-R helped in limiting the inﬂammation in mice challenged with H1N1
inﬂuenza virus (Walsh et al. 2011).
As of now, to kill EBOV, we do not have a speciﬁc
anti-viral drug. Many anti-viral drugs are being tested.
Therefore, the current treatment relies only on supportive therapy to revive. Recently, it has been discovered that antibodies can effectively block the entry of
this virus so it can be employed as therapy for control
of Ebola infection in humans (Corti et al. 2016). There is
a search for a new drug to control lethality caused by
this virus (Choi & Croyle 2013; Kilgore et al. 2015). Clomiphene and Toremifene are estrogen receptor drugs
which were found to inhibit EVD infection in mice.
These drugs inhibit virus entry and also inhibit EBOV
fusion to host cells (Johansen et al. 2013). Ion channel
blocking agents like amiodarone were reported to
inhibit entry of EBOV into the cells (Gehring et al.
2014). These drugs combined with anti-viral drugs can
be candidates for the treatment of EVD in places where
medical facilities are less. Recently, a group of researchers has tested the anti-ﬂu drug Favipiravir in EVD
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treatment (Nagata et al. 2015; Sissoko et al. 2016)
which indicated its use in patients with medium to
high viremia. However, it turned out to be not effective
in the case of very high viremia (Sissoko et al. 2016).
Convalescent whole blood (CWB) and convalescent
plasma (CP) therapy intends to transfuse the blood/
plasma from disease survivors and helps in neutralizing
and reduce virus load, till the time patients own
immune system can destroy the invader (Van
Griensven et al. 2015). Up to 10 ml/kg BW of CP can be
obtained on 15 days interval from a plasma donor. It
has longer shelf-life. However, CP usage is superior to
CWB as there might be a problem of the immune
response against leukocyte antigens and febrile transfusion reactions with the risk of bloodborne pathogen
transmission (Erhabor & Adias 2011). WHO also recommended the use of whole blood products and convalescent serum (Gulland 2014) during critical conditions.
Before transfusion, exhaustive testing of plasma is
required for residual EBOV RNA, and other potential
viruses like HIV, HBV, HCV, and syphilis. Puriﬁed IgG
from survivors given to challenged non-human primates two days post infection, prevented death, showing the importance of antibody preparations (Dye et al.
2012). RNAi has been a promising technology that can
be used for the treatment of EBOV (Warren et al. 2010).
A pyrazine carboxamide derivative T-705 (Favipiravir) is
in the last phase of the clinical trial and has yielded satisfactory results in a mouse model against EBOV. Favipiravir neither inhibits the DNA or RNA synthesis
(inhibit RNA-dependent RNA polymerase) in cell lines
of mammalian origin, nor it is toxic to cells (Oestereich
et al. 2014). Brincidofovir is a cidofovir analogue conjugated with lipid and also possesses anti-viral activity. It
has activity against dsDNA viruses but how it prevents
Ebola replication is still a question (Florescu & Keck
2014; Dunning et al. 2016). The broad spectrum antiviral agent alisporivir which inhibits the host protein
cyclophilin A (CypA) seems to have not much effect on
Ebola strains (Makona and Mayinga) as this virus does
not require CypA for replication (Chiramel et al. 2016).
BCX4430, viral RNA polymerase inhibitor was protective against EBOV in mice (Fauci 2014; Warren et al.
2014). A protein named double-stranded RNA binding
protein 76 (DRBP76) interacted with viral proteins, with
RNAs and with PKR, an interferon-induced anti-viral
kinase and also inhibited polymerase function of EBOV
(Shabman et al. 2011). The siRNA technology targeting
L-protein of RNA polymerase was used to inhibit EBOV
replication hence can be used as a post-exposure treatment to EBOV infection (Geisbert et al. 2010). The siRNAs and phosphorodiamidate morpholino oligomers,
PMO aimed at ZEBOV RNA polymerase L-protein prevented EVD in non-human primates (Warren et al.
2010; Geisbert et al. 2010). PMOs tend to target VP35
and VP24 that protects from the disease (Warren et al.
2015). Two new drugs based on antisense PMOs (AVI-
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Table 5. Different available therapies for Ebola virus treatment.

Type of therapy
siRNA therapy

Name of molecule/modality
TKM-Ebola

Antiviral drug

AVI-7537

Modus operandis
Cocktail of three siRNAs
targeting L, VP24, and
VP35 genes
Through gene silencing

Favipiravir (T-705), a
pyrazinecarboxamide derivative

ZMapp
Nucleotide
analogue
Induction of
Niemann-Pick
C1 mutant
phenotype
Repurposed drug

Convalescent
plasma (CP)
therapy

Inhibit viral RNA-dependent
RNA polymerase activity
and induce lethal RNA
mutations
Brincidofovir (CMX001)
Improved bioavalability and
activity against dsDNA
viruses
Combination of humanized
Conformational epitopes of
GP2 or GP trimer stem
monoclonal antibodies (c13C6 +
c2G4 and C4G7
region are targeted
BCX4430
Nucleoside RNA polymerase
inhibitor, incorporate into
growing RNA and lead to
premature termination
U18666A/clomiphene/toremiphene Membrane fusion and virus
induce cholesterol accumulation
escape is prevented
in lysosomes and inhibit Ebola
virus infection
FTY720 (FDA-approved drug for
Prevent cytokine storm and
multiple sclerosis)
sepsis, reduce
inﬂammation
FX06 (anticoagulant therapy)
Fibrin-derived peptide help
in vascular leakage
Rosuvastatin, atorvastatin, and
Reduction of cholesterol
pravastatin (lipid lowering drugs)
content affect the
biosynthesis machinery in
Ebola virus
Chloroquine, hydroxychloroquine
Prevent endosome
(antimalarial/lupus erythematous
acidiﬁcation and Ebola
/rheumatoid arthritis treatment
virus is trapped inside
with its anti-inﬂammatory
endosome
properties
rNAPc2 (recombinant nematode
Modulation of coagulation
anticoagulant protein c2)
factors
Suramin (anti-trypanosomal agent) Anti-heparin activity,
interfere with viral
replication and viral entry
into the cell
Plasma for Ebola survivors
Providing highly speciﬁc
antibodies and replenish
lost serum components

Model organism
(onto which the
test has been
conducted)
Monkeys

Company
Tekmira, Canada

Mice and monkeys Sarepta Therapeutics

Mice

Toyama Chemical,
Japan

Human (but not
for ebolaspeciﬁc)
Macaques

Chimerix of Durham,
North Carolina

Mice

In vitro

References
Geisbert et al.
(2010)
Warren et al.
(2010); Iversen
et al. (2012);
Heald et al.
(2014)
Smither et al.
(2014);
Oestereich
et al. (2014)
Florescu et al.
(2015)

Mapp
Haque et al.
Biopharmaceutical,
(2015); Kilgore
San Diego, California
et al. (2015)
BioCryst
Warren et al.
Pharmaceuticals, Inc.,
(2014)
Durham, North
Carolina
A chemical supplied by Carette et al.
several vendors across (2011)
the world

Human

Sigma/Novartis

Japtok and
Kleuser (2009)

Human

MChE-F4Pharma,
Vienna, Austria
By several vendors
across the world

Wolf et al.
(2015)
Calza et al.
(2012); Haque
et al. (2015)

Human

By several vendors
across the world

Primates

ARCA biopharma,
Colorado
Germanin, Bayer

Madrid et al.
(2013); Olsen
et al. (2013);
Kuehne et al.
(2016)
Geisbert et al.
(2003)
Henß et al.
(2016)

Human

In vitro

Rhesus macaques

NA

Human

NA

Cynomolgus
macaques

NA

Mice and guinea
pigs
Guinea pigs or
chimpanzees

NA

Virus-like particles DNA vectors expressing GP and
(VLPs)
VP40 proteins in human 293T
cells

Mice

NA

Trojan-horse
antibodies

Mice

NA

Wec et al. (2016)

In vitro

NA

In vitro

NA

Teimoori et al.
(2016)
Wang et al.
(2016)

Viral-vectored
vaccines

DNA vaccine

Human
transbodies
TmPyP4

Recombinant chimpanzee
adenovirus serotype 3 vector
Recombinanat Vesicular stomatitis
virus

GP gene

Venezuelan equine encephalitis
virus (VEEV) replicons
Inserted NP/GP

GP/NP
Antigen presentation by
both MHC-I and II

Morphologically similar to
virus and provoke
protective immune
response
Bispeciﬁc antibody
Speciﬁc for NCP1 or GP
receptor binding site
coupled to mAb against
conserved surface
exposed GP epitope
Cell penetrable human ScFv against Inhibit egress of EBOV VLPs
VP40
from hepatocytes
Cationic porphyrin
Inhibition of L gene of
EBOV

NA

Jahrling et al.
(2007); Dye
et al. (2012);
Mendoza et al.
(2015)
Choi et al.
(2015)
Jones et al.
(2005); Qiu
et al. (2009);
Falzarano et al.
(2011)
Pushko et al.
(2003)
Sullivan et al.
(2009); Hoenen
et al. (2012)
Ye and Yang
(2015); Carra
et al. (2015)
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6002, AVI-6003) and lipid nanoparticles (LNP)/siRNA
(TKM-Ebola) are in phase I clinical trials. Encapsulation
with LNP gives an effective drug delivery, but they
need several dose regimens to achieve efﬁcacy (Choi &
Croyle 2013; Thi et al. 2015). The miRNA technology
has also shown good results during in vitro trials
(Sheng et al. 2014). Understanding the mechanism of
virus entry through two-pore channels paved the way
in testing certain molecules such as Tetrandrin that
inhibits or halts virus entry into the cells and prevents
the disease (Sakurai et al. 2015).
Meanwhile searching for new drugs, some of the
drugs have been repurposed for therapy (Table 5).
Chloroquine and its structural analogs including
hydroxychloroquine, pamaquine, primaquine, and
plasmaquine, etc. are antimalarial drugs. These are also
considered as a lysosomotropic agent that prevents
endosomal/lysosomal acidiﬁcation. Based on the literature data, such endosomal/lysosomal acidiﬁcation inhibition by potential therapeutic agents such as
chloroquine are highly effective against viral infections
and associated pathologies such as of EBOV. Intraperitoneal administration of chloroquine protected 100%
of monkeys challenged with EBOV with a dose of 90
mg/kg BW, 4 hours before infection (Olsen et al. 2013).
Of note, in Liberia when the mass administration of the
antimalarial drug was adopted, reduction in fever status was observed during Ebola outbreak (Kuehne et al.
2016). Rosuvastatin, atorvastatin, and pravastatin are
the statins which reduce inﬂammatory action and are
known to reduce C-reactive protein (CRP) and TNFa. It
also hampers cholesterol supported EBOV membrane
biosynthesis (Haque et al. 2015). EBOV infection leads
to overexpression of the procoagulant tissue factor
and endothelial cells also participate in coagulation
disharmony characteristic of Ebola infection. In
macaque model recombinant nematode anticoagulant
protein c2 (rNAPc2) improved survival and provided an
additional therapeutic regimen which can be adapted
along with several other therapies (Geisbert et al.
2003b). Suramin which is used as an anti-trypanosomal
agent can also be used as an anti-viral agent to treat
EVD and Chikungunya due to its competitive anti-heparin activity. It also can interfere with viral replication
and viral entry into the cell (Henß et al. 2016). In the
face of unavailability of any suitable treatment procedures for curing the affected persons of this dreaded
disease, use of passive immunization (neutralizing antibodies) protocol was opted by transferring the sera
from healthy persons which recovered from EVD
(Saphire 2013). But it is not sufﬁcient alone to give
100% protection after the onset of viremia (Mire et al.
2016). Additionally, ZMapp which possess humanized
mouse antibodies showed promising results in nonhuman primates (Wong, Qiu, et al. 2014; Zhang et al.
2014) and consequently, on 12 August 2014, the WHO
approved the use of ZMapp for the treatment of EVD.
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These mAbs are expressed in the glycomodiﬁed Nicothiana benthamiana and found to be carrying better
anti-EBOV efﬁciency in animal models (Zhang et al.
2014). Bispeciﬁc Trojan-horse antibodies that can
broadly neutralize all known ﬁloviruses were found to
protect mice from multiple EBOV infection (Wec et al.
2016). Recently, attempts have been made to evaluate
the anti-Ebola potential of human scFvs against VP40
envelope protein of EBOV that plays an important role
in its life cycle. These antibodies were found to block
the Ebola VLPs in hepatic cells which are transduced
with pseudo-Lentivirus particles (Teimoori et al.2016).
This suggests that these transbodies might be effective
against EBOV as well interfering with their replication
in the cell. Also, it has been found that there exists a
conserved guanine-rich sequence within the L gene of
EBOV that can form quadruplex RNA and it can be targeted by cationic porphyrin TmPyP4 that leads to inhibition of L gene expression (Wang et al. 2016).
Progress is on the way towards developing effective
therapeutics as some lead has been obtained by identifying the weak spots in EBOV structure. Looking into
the demand of ZMapp and existing limited
manufacturing facilities, an alternative approach such
as the use of the plant as bioreactors for the bulk production of ZMapps, have been proposed. Certain host
factors are also responsible for virus replication and
survival. To identify them insertional mutagenesis can
be employed which is a high-throughput method
where host genes are disrupted. This helps in identifying those genes required for virus replication and can
be used as a drug target in future (Cheng et al. 2016).
This gives direction to further identiﬁcation of viral targets or host targets which could be used to control or
inhibit this virus disease in the patient. Molecular docking studies of EBOV-glycoproteins have been carried
out recently which could provide insights into drug
designing (Ahmad et al. 2016; M Alam El-Din et al.
2016). Advances in designing effective therapeutic
agents and drugs by utilizing emerging and upcoming
options, namely cytokines, recombinant proteins, RNAi
technology, Toll like Receptors, avian egg antibodies,
nano-medicine, immunomodulators, probiotics herbs,
need to be explored to the desired potential to counter
EBOV (Geisbert et al. 2010; Dhama, Chakraborty, et al.
2013; Dhama, Saminathan, 2015; Malik et al. 2013; Gao
& Yin 2014; Arntzen, 2015; Streatﬁeld et al. 2015; Yao
et al. 2015; Cross et al. 2016; Iqbal et al. 2016).

13. Conclusions and future perspectives
EVD is one of the most common examples to refer
emerging or re-emerging zoonoses globally. Nonetheless, the disease is known since 1976, its severity,
exceptional infectious or contagious nature, acquiring
pandemic status during 2014–2015, has raised numerous questions before the health professionals and
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policy-makers. The emergence of Ebola as a threat has
cautioned all of us to get ready with arsenals for contending Ebola-like diseases through multidisciplinary
and collaborative approaches overcoming the national
boundaries. This is the right time to tackle the EVD
emergency through the development and use of stateof-art tools and techniques beﬁtting for conﬁrmatory
diagnosis, developing internationally suited surveillance, monitoring, and networking systems as well as
identifying the animal reservoirs. The urgency for
developing and use of both, the safe and efﬁcacious
vaccine and affordable anti-viral drugs are desperately
needed. Kinome, transcriptome, and exome analyses
may be helpful in identifying the genomic targets up
or down-regulated and also insight into siRNA and
miRNA generated during infection helping in developing efﬁcacious therapeutic regimens. This is an apt
time to think of for ‘One Health’ concept and come out
with a strategy to safeguard human, animal, and environment. Realizing the eventual impact of the threat
imposed by EVD, all pinpointed efforts must be
focused on achieving the goal of preventing and controlling the existence of EVD timely. The Ebola epidemic has been a humanitarian crisis in the three
worst affected countries in West Africa. Although WHO
has declared the end of Ebola, there is still a potential
risk of sporadic transmission of EBOV which could be
largely due to residual virus persistence in some survivors in West Africa (Brainard et al. 2016). The WHO is
urging public health authorities to remain on high alert
and ready to respond in any emergency (Stamm 2015).
Further, strong surveillance and emergency response
capacity need to be upheld, while care, screening, and
counseling also need to be provided for survivors.
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